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Abstract: 
Objectives: This study investigated the efficacy of Montmorency tart cherry (TC) alone 
and in combination with exercise on improving bone quality in young growing animals 
and the underlying mechanisms of action.   
Methods: Six-week-old female C57BL/6 mice were randomly assigned to 4 groups (n=12 
mice/group) in a 2x2 factorial design: control AIN-93G diet (CON), CON+exercise, TC 
(10% w/w), or TC+exercise. The exercise consisted of treadmill running for 30 min, 5 
d/wk at 12 m/min and a 5° incline. Body weights were recorded weekly. After 8 wks of 
treatment, mesenchymal stem cells (MSC) in the tibial bone marrow were quantified via 
flow cytometry fluorescent activated cell sorting (FACS). Trabecular and cortical bone 
microarchitecture in the femur and lumbar vertebrae was assessed using micro-computed 
tomography. Biomechanical testing was performed using finite element analysis (FEA). 
The relative abundance of RNA for genes involved in osteoblast and osteoclast 
differentiation and activity was determined using RT-PCR. Data were analyzed using a 2-
way ANOVA with TC and exercise as factors. 
Results: At the end of the study, no differences in body weight were observed. Trabecular 
bone volume in the femur and spine was increased with exercise and TC (p<0.05), but 
there was no interaction. Cortical bone thickness in the vertebra was also increased by TC 
and exercise (p<0.001), but not in the femur. Trabecular bone strength and stiffness were 
increased in the vertebra in response to TC and exercise, but only in response to TC in the 
femur (P<0.001). An increase in bone marrow MSCs occurred in response to exercise 
(p<0.01), but not TC. However, the combination of TC and exercise reduced nuclear 
factor of activated T-cells 1 (Nfatc1) femur gene expression, a key regulator of 
osteoclastogenesis (p<0.05). TC also increased bone morphogenetic protein (BMP)2 gene 
expression, a regulator of osteoblastogenesis.  
Conclusion: Our data indicate that TC and exercise alone had positive effects on bone 
quality by suppressing regulators of osteoclastogenesis and increasing regulators of 
osteoblastogenesis. Even though the effects of TC and exercise were not synergistic, the 
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Introduction to the Problem 
Osteoporosis is a degenerative musculoskeletal disease negatively affecting over 
200 million people worldwide [1]. Low bone mass and microarchitectural deterioration 
are hallmark characteristics of osteoporosis, and consequently a marked increase in bone 
fragility and risk of fracture.  Classic sites for osteoporotic fractures include those of the 
vertebrae, forearm, and proximal femur.  Individuals who experience an osteoporotic 
fracture are at significantly higher risk of experiencing another fracture [2] .  Osteoporotic 
fractures can be incapacitating, pose significant financial burden, and result in increased 
mortality rates [3]. Traditionally, white postmenopausal women have been considered 
one of the largest populations affected by osteoporosis; however men, other ethnicities 
(e.g. Asians and Hispanics), and all ages are susceptible depending on modifiable (e.g., 
sedentary, diet, or chronic inflammation) and non-modifiable (e.g., gender, age, or family 
history) risk factors [4]. Both types of risk factors contribute to one of two overarching 
determinants of osteoporosis, the ability to achieve optimal peak bone mass during 
growth and the loss of bone mass later in life.   
Based on guidelines developed by the World Health Organization (WHO), bone 
mineral density (BMD) T-scores are used to define osteopenia (T-score -1.0 to -2.5) and 
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osteoporosis (T-score < -2.5) [5]. It is estimated that approximately 54% of white 
postmenopausal women have osteopenia and another 30% suffer from osteoporosis [6].  
The prevalence of osteoporosis among women aged 50+ years is approximately 29.9%, 
but by the age of 80 years the prevalence increases to 77.1%.  In contrast, for men the 
prevalence of osteoporosis increases from 16% at 50+ years to 46.3% at 80 years [6] .  In 
2010, prevalence of the disease in the United States was estimated to be approximately 
10.2 million and by 2020 a projected 10.4 million more individuals will be affected [7]. 
Medical costs incurred by U.S patients with osteoporosis in 2005 were estimated to have 
been between 13.7-20.3 billion dollars [8]. Cumulative costs incurred by osteoporotic 
fractures are expected to increase to 22.8 billion dollars annually by 2016-2025 [7, 8].  
 The skeleton is a complex organ providing structure, locomotion, calcium 
storage, organ protection, and a compartment for the bone marrow. The skeleton is 
composed of two major subtypes of bone, trabecular and cortical, which are of significant 
interest in osteoporosis due to their potential influence on bone quality. Cortical bone, the 
dense outer layer of bone, provides a protective cover around the marrow space. The 
mature human skeleton is composed of approximately 80% cortical bone [9]. By 
comparison, trabecular or cancellous bone comprises 20% of the skeleton and forms a 
honeycomb-like structure within flat bones, such as the iliac crest, and in the ends of long 
bones [9]. Trabecular struts are organized into plates and rods and result in trabecular 
bone having a higher surface area to mass ratio than cortical bone. In general, cortical 
bone is stronger than trabecular bone, but has less elastic properties and can become 
brittle [10, 11]. Trabecular and cortical bone are composed of an organic matrix and 
inorganic salts [12]. The organic matrix is principally comprised of collagen, primarily 
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type I collagen, and also contains osteonectin, osteocalcin, bone sialoprotein II, bone 
morphogenetic proteins, and osteopontin, which are involved in regulating the catabolic 
and anabolic aspects of bone metabolism [13]. The inorganic portion of bone is 
composed largely of phosphate and calcium that form hydroxyapatite crystals within the 
collagen matrix and give structure to bone [12].   
Bone is a dynamic tissue constantly undergoing complex processes, including 
bone modeling and remodeling. Bone remodeling, a cycle of bone resorption and 
subsequent formation that occurs within the bone multicellular units (BMU), prevents the 
accumulation of micro-damage within the mature bone and maintains its structural 
integrity. In contrast, bone modeling involves the shaping and sizing of bone by the 
independent activities of osteoblasts and osteoclasts, and is the primary process occurring 
in the young growing skeleton [14]. Both bone modeling and remodeling are carried out 
by osteoblasts, osteoclasts, and osteocytes. Osteoblasts, which differentiate from 
mesenchymal stem cells (MSCs), secrete the protein matrix (e.g. type 1 collagen, 
osteocalcin, osteonectin, and bone sialoprotein) that is then mineralized and thereby 
increases bone mass [15].  Osteoclasts on the other hand, originate from hematopoietic 
stem cells (HSCs) and resorb bone by creating an acidic micro-environment within the 
BMU and secreting proteases that catabolize proteins. Imbalances in the remodeling 
cycle that favor the catabolic activity of osteoclasts over the anabolic activity of 
osteoblasts contribute to the development of osteoporosis. Therefore, regulatory proteins 
of osteoclast and osteoblast differentiation and activity are highly relevant in the 
maintenance of healthy bone.  Key regulators in osteoblast differentiation include runt 
related transcription factor 2 (Runx2) and Osterix, which promote the allocation of MSCs 
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to an osteogenic lineage [16]. The enzyme, alkaline phosphatase (ALP), which promotes 
extracellular matrix mineralization of bone by releasing phosphate, and procollagen I N-
terminal peptide (PINP), a by-product of collagen formation are both considered 
indicators of osteoblast activity [17] .  Furthermore, bone mineralization is regulated by 
proteins such as osteocalcin (OCN), phosphate-regulating neutral endopeptidase X 
(Phex), and peroxisome proliferator-activated receptor gamma (Ppar-γ) [17-19].  In terms 
of osteoclast differentiation, macrophage colony-stimulating factor (M-CSF), receptor 
activator of nuclear factor kappa-B ligand (RANKL), and nuclear factor of activated T-
cells 1 (NFatc1) are key promoters of osteoclastogenesis while osteoprotegrin (OPG), 
acts as decoy receptor for RANKL [20, 21]. In contrast, cathepsin K and tartrate-resistant 
acid phosphatase (TRAP) are two of the major proteases involved in the degradation of 
the protein matrix [21, 22].  In addition to the regulator of osteoblast and osteoclast 
differentiation and mediators of their activity, pro-inflammatory cytokines such as 
interleukin (IL)-1 and IL-6, produced mainly by activated macrophages, increase the 
expression of M-CSF and RANKL that in turn promote osteoclastogenesis and bone 
resorption [21] .  Osteocytes, which are bone cells formed when osteoblasts become 
embedded within the matrix, play an active role in regulating bone turnover and serve as 
the mechano-sensory cells in the bone with the capacity to stimulate osteogenesis via the 
Wnt/β-catenin pathway [23, 24]. 
Current FDA-approved pharmaceutical treatments for osteoporosis target either 
the osteoclast (i.e., anti-resorptive agents) or osteoblast (i.e., anabolic agents) activity.  
Anti-resorptive drugs (e.g. bisphosphonates or Denosumab) inhibit osteoclast 
differentiation and activity. Furthermore, bisphosphonates promote the induction of 
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osteoclast apoptosis [25]. The only FDA-approved anabolic option is Teriparatide, a 
recombinant human parathyroid hormone, that increases osteoblast differentiation and 
inhibits osteoblast apoptosis [26]. Anti-resorptive drugs are often considered a first line 
treatment option for osteoporosis, but in severe cases anabolic agents may be used alone 
or in combination with anti-resorptive agents [27]. While these drug therapies have 
shown to be effective in the reduction of fracture risk and consequently in the treatment 
of osteoporosis, they may not be ideal for long-term use due to side effects, cost and 
issues with compliance [28]. Therefore, investigation of novel alternatives is imperative. 
One of the best predictors of osteoporosis risk is peak bone mass [29, 30]. Peak 
bone mass is defined as the quantity of bony tissue accrued by the end of skeletal 
maturation [29].  Females attain peak bone mass approximately 2 years after menarche, 
while males continue to accrue bone into their early twenties [30]. The higher the peak 
bone mass, the greater the margin for bone loss before becoming osteoporotic and at 
increased risk of facture.  Identifying strategies for achieving an optimal peak mass would 
be a one ideal strategy to prevent osteoporosis. 
Attainment of a higher peak bone mass may be achieved through adequate dietary 
intake (e.g., protein, calcium, and vitamin D), exercise, and avoidance of lifestyle 
behaviors that have negative effects on bone (e.g., smoking and alcohol).  Exercise, 
namely weight-bearing exercise, is a well-established modifiable lifestyle factor that 
promotes the accumulation of bone mass [31].  It is widely understood that exercise that 
increases the forces experienced by bone resulting in micro-damage to bone tissue which 
necessitates repair or increased bone formation. The net effect is an increase in BMD. 
Other proposed mechanisms for enhanced bone formation associated with exercise 
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involve increased prostaglandin release, increased blood flow, and hormonal alterations 
[32]. Recently understanding the role of MSC in the response to weight-bearing exercise 
has become an area of interest.  A study by Wallace et al. [33] showed that with short-
term treadmill running (i.e., 30 min/d for 5 d) mice exhibit a decrease in bone marrow 
derived MSCs, thus suggesting their potential lineage allocation away toward osteoblasts. 
Another study by Maredziak et al. [34] examined the effects of a chronic treadmill 
running (i.e., 45 min/d, 3 d/wk, for 5 wks) and reported an increase in MSC populations 
in the exercising groups as well as a decrease in Ppar-γ signifying a reduction in the 
adipogenic lineage allocation of MSCs. These studies, taken together suggest that 
weight-bearing exercise not only increases the number of MSCs in the long-term, but 
may also increase their potential to differentiate into active osteoblasts [33, 34]. An 
increased population of osteoblasts likely promotes osteogenesis and consequently the 
accrual of a higher peak bone mass.  
Likewise, dietary intake is paramount to the attainment of a high peak bone mass. 
Nutritional adequacy of protein, calcium, and vitamin D and their implications on 
osteoporosis are widely recognized by the scientific community as well as the general 
population. Less credited, but still critical nutrients, include: Zn, Cu, Mn, and vitamin K 
[35].   However, emerging evidence suggests a role of non-nutritive bioactive compounds 
(e.g., polyphenols) may play a pivotal role in skeletal health. Functional foods, including 
dried plum, green tea, and soy have shown promising osteoprotective effects [36-46]. The 
distinct ability of these foods to promote bone quality may be derived in part from their 
rich polyphenolic profiles [47, 48]. Polyphenols elicit potent anti-inflammatory and 
antioxidant effects and in some instances directly interact with functional proteins (e.g. 
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receptors, growth factors and cytokines). However, recent findings also suggest that the 
beneficial effects exerted by some of these functional foods may be due to other 
components such as non-digestible carbohydrates (e.g., fructooligosaccharides and 
galactooligosaccharides) [49]. Non-digestible carbohydrates elicit a number of favorable 
effects, including the promotion of beneficial bacteria (e.g. Bifidobacterium), a reduction 
of pathogenic bacteria, and enhanced short chain fatty acid (SCFA) production [50]. In 
vitro and in vivo, SCFA supplementation with propionate and butyrate has been shown to 
downregulate TRAF6 and NFatc1 expression, osteoclastogenesis, and bone resorption 
[51].  
Recently, our laboratory has investigated the osteoprotective effects of 
Montmorency tart cherries, which have a similar polyphenolic profile as dried plum 
containing high amounts of hydroxycinnamic acids and anthocyanins. Tart cherries are 
among the most polyphenol rich cultivars of cherries and they area also abundant in 
oligosaccharides including fructooligosaccharides and galactooligosaccharides [49]. 
Dietary supplementation with dried Montmorency tart cherry powder was shown to be 
efficacious in attenuating age-related bone loss and in some sites exhibit anabolic effects 
(manuscript under review). These findings provide evidence that suggests tart cherry 
supplementation suppresses the resorptive activity of osteoclasts, and may even promote 
the bone forming activity of osteoblasts.  Whether or not these effects are mediated by 
altering the differentiation of osteoblasts or later phases of bone mineralization is not 
clear, but these findings have raised the question of whether or not combining tart cherry 




Purpose and Hypothesis: 
Therefore, the purpose of this study is to investigate the effects of tart cherry alone and in 
combination with exercise as a means to improve peak bone mass and bone quality in 
growing female C57BL/6 mice, while gaining insight into the underlying mechanisms of 
action.  The hypothesis is that tart cherry and exercise in combination will yield a 
synergistic effect on bone quality in growing skeletons, which exceeds either treatment 
administered individually.  The synergistic effect will result from an increase in MSC 
populations, in response to tart cherry and exercise, and their ability to differentiate into 
active osteoblasts.   
 
Specific Aims and Working Hypotheses: 
The hypothesis will be tested by accomplishing the following aims: 
Specific Aim 1:  To compare the effects of the tart cherry, exercise, and their 
combination on bone quality (i.e. , BMD, trabecular and cortical microarchitecture, and 
biomechanical properties) in young growing animals.  
Working hypothesis Aim 1: The combination of tart cherry and exercise will yield a 
synergistic effect on bone quality exceeding either variable administered individually.  
 
Specific Aim 2:   To determine the effect of tart cherry, exercise and their combination 
on bone marrow MSC populations and their progression towards an osteoblast lineage.  
Working hypothesis for Aim 2: Tart cherry combined with exercise will result in a 




Specific Aim 3:  To assess the alterations in regulators of osteoblast (e.g. Runx2 and 
Osterix) and osteoclast (e.g. RANKL, OPG, and NFatc1) differentiation that occur in 
response to treatments. 
Working hypothesis for Aim 3: The combination of tart cherry and exercise will, to a 
greater magnitude, promote osteoblastogenesis and suppress osteoclastogenesis compared 
to all other treatment groups.  
 
Specific Aim 4:   To evaluate the effects of tart cherry, exercise or their combination on 
osteoblast and osteoclast activity by examining circulating levels of biomarkers of 
resorption (i.e., CTX) and formation (i.e., P1NP), and local indicators of osteoblast 
activity and mineralization (e.g. type 1 collagen, OCN, Phex, and Ppar-γ), and osteoclast 
activity (e.g. CathK). 
Working hypothesis for Aim 4: Tart cherry and exercise in combination will, to a 
greater magnitude, stimulate osteoblast activity and inhibit osteoclast activity above all 
other treatment groups.  
 
Specific Aim 5: To assess alterations in antioxidant status indicated by gene expression 
of key enzymes involved in scavenging free radicals in bone (e.g. Gpx1 and SOD1) 
resulting from tart cherry, exercise or their combination. 







As is the case with any research, the study presented here is not without 
limitations.  These limitations include lack of information related to: 1) whether or not 
protein levels of key regulators and indicators is affected; 2) whether or not alterations in 
osteoblast and osteoclast activity occurred earlier in the intervention period; 3) whether or 
not gender and age could influence the response; and 4) whether or not the response 
observed here, especially in the vertebra would translate to bipedal animals. At this time, 
data supporting the site-specific mechanisms through which tart cherry and exercise 
alters bone quality are based on regulators of bone modeling and remodeling at the 
transcriptional level.  It remains to be seen if tart cherry and exercise induce protein 
changes, which will be determined in subsequent analyses. Additionally, this study is 
limited to analysis of effects on bone metabolism after 8 weeks of treatment and changes 
occurring earlier may not be apparent. This study is also limited to providing evidence for 
the efficacy of tart cherry and exercise in young female mice. Subsequent studies will be 
necessary to determine the effects in both male and aged mice. 
Lastly, the use of an animal model, specifically a quadruped animal model, in this 
study could be considered a limitation in some respects. Loading effects of exercise in 
this model are not likely to directly translate into biped animals. Therefore, while the 
study design simulates the effects of diet and exercise on the development of peak bone 
mass, the site-specific outcomes may not translate to humans.  Subsequent clinical studies 









  REVIEW OF LITERATURE 
Introduction to Osteoporosis 
Osteoporosis is a chronic degenerative bone disease affecting millions of 
individuals and causing an estimated 9 million fractures worldwide each year with 4.5 
million occurring in the United States and Europe alone [52]. The World Health 
Organization (WHO) defines osteoporosis as a bone mineral density (BMD) more than 
2.5 standard deviations below the population’s mean BMD and osteopenia between 1 and 
2.5 standard deviations below the mean BMD for young healthy women [2]. Low bone 
mass is the hallmark characteristic of osteoporosis; however, the disease is also marked 
by micro-architectural deterioration, bone fragility, and consequently fracture risk [2].   
Traditionally, there have been two subtypes of osteoporosis considered, primary 
and secondary, which differ based on etiology. Primary osteoporosis is the result of 
classic risk factors (i.e. age related bone loss) (Table 1), whereas secondary osteoporosis 
is the result of endocrine, metabolic, or immune disorders [53]. Therefore, management 
of modifiable risk factors is critical in the prevention of osteoporosis in all individuals, 
but especially in those with multiple non-modifiable risk factors (e.g. age and gender). 
White postmenopausal women are one of the highest risk populations for developing 
osteoporosis; however, men, other ethnicities, and individuals of all ages are susceptible 
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when subjected to numerous risk factors (Table 1). Postmenopausal women are more 
susceptible to osteoporosis due to associated declining in estrogen. Perimenopausal rates 
of bone loss from the spine and hip are on average 0.018 and 0.10 g/cm2 per year, 
respectively. However, postmenopausal rates increase to 0.022 and 0.13 g/cm2 per year, 
respectively [54]. Overall, women lose approximately 50% of their trabecular bone mass 
and 30% of their cortical bone mass over their lifetime, but half of this loss occurs in the 
first ten years after menopause [54]. 
 
Table 1: Risk factors for the development of osteoporosis [4]. 
 
Screening and Prevalence of Osteoporosis 
 Screening and diagnosis of osteoporosis are of critical importance due to the 
increasing prevalence and the tendency for diagnosis to occur post fracture. The gold 
Non-Modifiable Risk Factors Modifiable Risk Factors 
Previous Fracture Physical activity 
Female  Vitamin D intake & sun exposure 
Ageing Calcium intake 
Family history (maternal) of fracture Alcohol consumption 
Primary and secondary amenorrhea  Smoking 
Early menopause Corticosteroid use 
Osteopenia Low body weight 





standard for diagnosis of osteoporosis is dual-energy x-ray absorptiometry (DXA), which 
provides an aerial measurement of BMD. Based on the guidelines set for by the National 
Osteoporosis Foundation and College of Preventative Medicine, DXA scans are 
recommended for women beginning at 65 years of age and men beginning at 70 years of 
age when no risk factors are present. Both men and women who have risk factors (e.g. 
modifiable and non-modifiable) are advised to get DXA scans beginning at age 50. 
However, adherence to routine screening guidelines is uncommon [28, 55]. Therefore, 
osteoporosis often goes undiagnosed, which has negative consequences on fracture 
prevention [56]. While BMD is used to diagnose osteoporosis, a better indicator of 
fracture risk would include evaluation of trabecular and cortical bone microarchitecture. 
However, clinical screening using computed x-ray tomography would be required to 
evaluate bone microarchitecture and at the present it is neither economical or practical 
[53]. 
Based on BMD measurements it is estimated that approximately 54% of white 
postmenopausal women have osteopenia and 30% have osteoporosis. The prevalence of 
osteoporosis among women who are 50 years of age is approximately 5%, but by the age 
of 85, the prevalence of osteoporosis increases to 50%. By comparison, for men the 
increase is from 2.4% to 20% in these two age groups [57]. In 2010, the prevalence of 
osteoporosis in the United States was estimated to be approximately 10.2 million and was 
expected to increase to more than 10.4 million by 2020 [7]. Medical costs incurred by 
Americans with osteoporosis in 2005 were estimated to be between 13.7-20.3 billion 
dollars and cumulative costs incurred due to osteoporotic fractures were projected to 




Classically, the most common sites for osteoporotic fractures include the spine, 
forearm, and hip. Individuals who endure one fracture have a significantly higher chance 
of experiencing another. Based on the prevalence of osteoporosis, current treatment 
options, and population demographic shifts, Wolfe and Pfleger estimated that more than 
50% of women aged 50 years and older will experience an osteoporotic fracture in their 
lifetime [57]. Hip fractures are considered to be one of the most devastating and 
debilitating  outcomes of osteoporosis and are a major public health concern [58]. An 
estimated 1.66 million hip fractures occurred worldwide in 1990 and this number is 
expected to rise to 6.26 million by 2050 [59, 60].  Since 1990, the incidence of hip 
fractures has increased with the highest rates occurring in North America and 
Scandinavian countries [59]. It has been well established that hip fractures lead to 
increased mortality rates. A study by Sernbo and Johnell [3] reported that 34% of men 
and 20% of the women died within the first year of hip fracture. Additionally, the study 
examined 1,429 cases of hip fracture worldwide and reported the average cumulative cost 
of a hip fracture, including surgery, to be $26,000 [3]. However, Panula and colleagues 
[61] followed hip fracture patients (n=428), 65 years of age and older, and showed a 
mortality rate of 27.3% after the first year and 79% at the end of a 9 year follow-up [61]. 
Fractures are costly, debilitating, and in the case of hip fracture may lead to increased 
mortality; therefore, fracture prevention is of paramount importance. 
Based on the increasing prevalence of osteoporosis, the status of bone health is a 
global concern. The development of osteoporosis stems from two overarching 
determinants: the failure to develop a high peak mass early in life and loss of bone mass 
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with age or resulting from exposure to risk factors. The accrual of a high peak bone mass 
is regarded as the single greatest determinant in the development of osteoporosis [29, 62]. 
Consequently, targeting development (puberty) is favorable in prevention.  
Peak Bone Mass and Osteoporosis 
 Peak bone mass is regarded as the greatest predictor in the development of 
osteoporosis [29]. Peak bone mass is considered the quantity of bone accrued by the end 
of skeletal maturation. Achievement of peak bone mass occurs after the cessation of 
puberty. For females this usually occurs between 15-20 years of age and between 20-25 
years in males [63]. Peak bone density, a measure of bone mass per bone volume, 
measurements are similar between genders. However, peak bone mass, independent of 
volume, may differ depending on factors such as an individual’s height and frame size 
[64]. During pubertal growth, sex steroids (e.g. estrogen and testosterone), growth 
hormone (GH), and insulin-like growth factor 1 (IGF-1) increase significantly [65]. GH is 
known to stimulate pre-chondrocyte and pre-osteoblast proliferation as well as IGF-1 
production, which subsequently promotes chondrocyte and osteoblast differentiation and 
therefore cartilage and bone formation, respectively [65]. Growth plate osteoblasts 
contain androgen receptors, which testosterone and estrogen can bind to induce 
epiphyseal fusion resulting in the cessation of bone growth or elongation  [64]. Weise and 
colleagues found that higher levels of estrogen resulted in increased rates of plate 
senescence and epiphyseal fusion [66]. Furthermore, estrogen acts to inhibit bone 
resorption through promoting osteoclast apoptosis [67]. A better indicator for the 
development of peak bone mass in females is the onset of menarche.  During pubertal 
growth, menarche occurs concurrently with the elevation in estrogen, which promotes 
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epiphyseal fusion. Normally, no further gains in peak bone mass are observable in 
females within 2 years of menarche [62]. 
Rate of bone mass accrual changes throughout skeletal maturation. Based on the 
work of Soyka and colleagues [64], bone mass accrues throughout childhood with peak 
rates occurring during early to mid-puberty before slowing in late puberty (Figure 1).  
The achievement of a high peak bone mass is critical as it allows for a greater margin of 
bone loss before an individual develops osteopenia and subsequently osteoporosis. 
Consequently, years 11-14 for females and 13-17 for males are critical periods to target 
for maximizing peak bone mass [64].  Lifestyle choices such as diet and exercise have a 
significant effect on the accrual of bone early in life, estimated to influence 20-40% of 
adult peak bone mass [68, 69]. Therefore, targeting modifiable lifestyle factors (i.e. diet 
and exercise) during development may promote the development of a high peak bone 
mass, and be efficacious in the prevention of osteoporosis.  
 
Figure 1: Rates of vertebral bone mass accrual by age females (○) and males (•) [64]. 
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Bone Anatomy and Structure 
The skeleton is a complex organ composed of inorganic salts and an organic 
matrix [12]. The skeleton provides structure, calcium storage, locomotion, organ 
protection, and houses the bone marrow. By weight, the inorganic salt phase of bone 
tissue makes up approximately 60% of the skeleton [70]. This phase is composed of 
hydroxyapatite, a crystalline structure of calcium and phosphorus [Ca3(PO4)2]3Ca(OH)2 
[70]. Hydroxyapatite crystals are plate shaped and contain numerous impurities including:  
1) carbonate in place of phosphate, 2) potassium, strontium, magnesium, or sodium in 
place of calcium, and 3) chloride or fluoride in place of hydroxyls. These impurities 
interfere with many bone processes including mineral homeostasis and remodeling [70]. 
The organic phase of bone makes up for nearly 30% of total bone weight. This phase is 
composed of numerous proteins, of which type I collagen is the most abundant.  Type I 
collagen is responsible for ~90% of the organic matrix with the remaining 10% being 
non-collagenous proteins [70]. Some of these non-collagenous proteins include 
osteocalcin, osteonectin, osteopontin, and bone sialoprotein [71]. However, type I 
collagen is the primary structural component of the protein matrix while the non-
collagenous proteins contribute to other biological functions, including affecting 
osteoclast and osteoblast function, via cytokines or growth factors [70].  
Bone may be further classified into two subtypes: cortical bone and trabecular 
(i.e., cancellous) bone. Cortical bone is the dense outer layer of bone surrounding and 
protecting the marrow space. Cortical bone in healthy adults has a porosity of less than 
5%, but greater porosity is commonly seen in developing bones or in the aging skeleton 
[9]. The outer layer of cortical bone is sheathed by the periosteum while the inner surface 
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is covered by the endosteum. The periosteum is fibrous connective tissue anchored to the 
periosteal surface of the cortical bone via collagen fibers. The endosteum is a membrane 
on the endosteal surface of cortical bone which is in contact with the marrow space and 
trabecular bone. Bone formation on the periosteal surface exceeds resorption in growing 
skeletons resulting in an increased bone and medullary cavity diameter [9]. Cortical bone 
is dense and strong, but possesses few elastic properties, thus it has the potential become 
brittle. Cortical bone microarchitecture is assessed in terms of its thickness, area and 
porosity [10]. Trabecular bone, or cancellous bone, forms a complex meshwork 
resembling a honeycomb like structure. This trabecular network is composed of struts, 
which are can have a plate- and rod-like organization. Compared to cortical bone, 
cancellous bone possesses a much higher degree of anisotropy indicative of its greater 
elastic potential. 
Collectively, the mature human skeleton is made up of approximately 80% 
cortical bone and 20% trabecular bone [9]. However, this ratio differs depending on the 
site. Long bones such as the femur are composed of three sections: the diaphysis, 
metaphysis, and epiphyses (Figure 2). The diaphysis is regarded as the long hollow shaft 
residing between the proximal and distal ends of the bone. Consequently, this portion of 
the bone is primarily comprised of cortical bone. The metaphysis and epiphysis reside 
proximal to and distal to the growth plate at both ends of the long bone, respectively. 
Unlike the diaphysis the metaphysis and epiphysis contain significant amounts of 




Figure 2: Bone diaphysis, metaphysis, and epiphyses[72]. 
 
Bone Quality Effectors 
The skeleton is a dynamic organ that is constantly undergoing complex processes, 
including bone modeling and remodeling. Early in life, the skeleton primarily undergoes 
bone modeling [9]. During bone modeling, bones are shaped, reshaped, and positioned by 
the uncoupled anabolic activity of osteoblasts and catabolic activity of osteoclasts. Bone 
shape and size is altered in response to physiological factors (e.g. PTH and sclerostin) 
and/or mechanical loading [73]. Based on the magnitude and frequency of mechanical 
loading, bone modeling may be directed towards atrophy, maintenance, or hypertrophy of 
boney tissues [74] (Figure 3). Kontulainen and colleagues [75] showed this bone-
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modeling phenomenon in the dominant arm of tennis players, which exhibited a higher 
bone mass than the non-dominant arm due to exposure to repeated strain. Repeated strain 
elicited by the sport promotes hypertrophy where resorption (R) is less than formation 
(F).  Promoting an anabolic state of bone modeling is essential in the attainment of an 
optimal peak bone mass during skeletal maturation and consequently the prevention of 
osteoporosis later in life. Therefore, the incorporation of frequent mechanical loading 
during development is likely to prove effective in the prevention of osteoporosis. 
 
Figure 3: Effects of loading magnitude and frequency on bone modeling response [74]. 
Abbreviations: R resorption, F formation. Atrophy, resorption exceeds formation (R>F); 
Maintenance, resorption equals formation (R=F); Hypertrophy, formation exceeds 
resorption (R<F). 
 
As the skeleton ages, the primary metabolic process within the bone shifts from 
modeling to remodeling. The function of bone remodeling is foremost to maintain bone 
integrity through the resorption of old bone and subsequent formation of new bone. This 
cycle prevents the accumulation of micro-damage and associated bone fragility. 
Additionally, bone remodeling is critical in mineral homeostasis [76]. The bone 
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remodeling cycle has been described as four distinct phases: activation, resorption, 
reversal, and formation. Each phase involves the recruitment and activation of specific 
cells, namely osteoclasts and osteoblasts, organized into coupled basic multicellular units 
(BMUs) [77].  At a single point in time, there are millions of active BMUs at different 
stages in the remodeling cycle throughout the skeleton. 
During the activation phase of bone remodeling, multinucleated pre-osteoclasts 
are formed through the recruitment and subsequent fusion of mononuclear cells (e.g. 
monocytes and macrophages). These newly formed pre-osteoclasts bind to the bone 
matrix where they are signaled to differentiate into mature osteoclasts, a highly regulated 
process known as osteoclastogenesis.  Osteoclastogenesis is closely regulated by the 
cytokines, receptor activator of nuclear factor kappa-β ligand (RANKL) and 
osteoprotegrin (OPG). RANKL, which is excreted by cells of the osteoblast lineage and T 
cells, binds with the RANK receptor on the surface of pre-osteoclasts, activating nuclear 
factor-activated T-cells-1 (NFatc1), the master transcription regulator of osteoclast 
differentiation [21].  This process occurs via TNF receptor associated factor-6 (TRAF6), 
nuclear factor- κβ (NF-κβ) and c-Fos signaling pathways [78]. NFatc1 can also bind to its 
own promoter region and increase expression via auto-amplification. While RANKL 
stimulates osteoclastogenesis, its soluble decoy receptor, OPG, prohibits the RANK-
RANKL interaction and inhibits osteoclast formation. Both RANKL and OPG can be 
produced by osteoblasts in response to stimuli such as cytokines (e.g., tumor necrosis 
factor-alpha (TNF-α), IL-1, M-CSF and IL-6) and hormones (e.g., parathyroid hormone 
(PTH), 1,25-dihydroxy vitamin D, and calcitonin) [16]. Foods rich in bioactive 
components with anti-inflammatory properties such as dried plum’s polyphenols have 
22 
 
been shown to downregulate expression of RANKL, TNF-α, and NFATc1 thereby 
inhibiting osteoclastogenesis and consequently the activation phase [47, 79, 80].   
Initiation of the activation phase can also occur in response to micro-damage 
brought about by changes in mechanical loading from factors such as weight-bearing 
exercise [22].  The osteocytes, which are osteoblasts that become surrounded by bone 
matrix, are responsible for orchestrating this response [76]. These cells have cytoplasmic 
processes which maintain complex canalicular networks to surface cells, including 
osteoclasts and osteoblasts. Micro-damage or micro-fractures to bone result in the 
disruption of these osteocyte networks or osteocytes themselves. Damaged osteocytes 
secrete CSF and RANKL to promote osteoclastogenesis and subsequent resorption of the 
damaged bone [16]. Furthermore, osteocytes have a mechano-sensory function critical in 
detecting changes in mechanical loading [22]. Through site specific deletion of 
osteocytes it has been shown that bone does not respond to unloading, highlighting the 
important role that osteocytes play in these processes [24].  
 The maturation of pre-osteoclasts into mature osteoclasts marks the start of the 
resorption phase. During the resorption phase, mature osteoclasts form microscopic 
annular sealing zones on the bone surface and create an acidic microenvironment by 
secreting hydrogen ions (Figure 4). The low pH promotes the mobilization of the bone 
mineral component of the tissue. Osteoclasts also secrete cathepsin K, matrix 
metalloproteinase 9, gelatinase, and tartarate resistant acid phosphatase to digest the 
organic matrix [9]. Cathepsin K is considered a key enzyme involved in the digestion of 
the proteins matrix of the bone, namely type I collagen resulting in carboxy-terminal and 




Figure 4: Annular sealing zone and bone resorption [81]. 
[76, 82]. The ensuing digestion of bone results in the formation of Howship’s lacunae on 
cancellous bone surfaces and Haversian canals on cortical surfaces. Bone resorption in 
humans requires 2 to 4 weeks and culminates with osteoclast apoptosis [9]. 
The reversal phase occurs at the end of the resorption phase and transitions to the 
formation phase. Signaling required for this transition has not been well defined. A 
proposed mechanism is the release of TGF-β from the bone matrix during resorption that 
can inhibit osteoblast synthesis of RANKL, consequently downregulating 
osteoclastogenesis. Other proposed pathways that regulate this process include IGF-I and 
II, which are also released during resorption and are known to attract osteoblast 
precursors and promote their differentiation [83]. Overall during this phase an osteogenic 
environment is formed at remodeling sites [77]. 
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 The bone formation phase requires between 4 to 6 months in humans and is 
carried out chiefly by osteoblasts. Osteoblasts originating from pluripotent MSCs, which 
have the potential to differentiate into a number of different cell types including 
adipocytes, chondrocytes, and myoblasts [76]. Commitment of MSCs to the osteoblast 
lineage is mediated by the canonical Wnt/β-catenin pathway and its activation of the 
“master transcriptional regulator” Runx2 [9, 20]. The cell lineage progression known as 
osteoblastogenesis proceeds as follows: MSC, immature osteoprogenitor, mature 
osteoprogenitor, pre-osteoblast, and mature osteoblast (Figure 5).  
 
Figure 5: Mesenchymal stem cell lineages [84]. 
Following commitment to the osteoblast lineage, osteogenesis proceeds in three phases 
(i.e., proliferation, matrix maturation, and mineralization) with each phase exhibiting 




Figure 6: Phases of osteogenesis and protein expression [86]. 
The first phase is marked by continual proliferation of pre-osteoblasts. Osteoprogenitor 
cells in this stage express fibronectin, type 1 collagen, TGFβ receptor1, and osteopontin 
[20]. Transcriptional regulators of osteoblastogenesis include osterix and Runx2. Osterix, 
like Runx2, promotes differentiation of osteoblasts, but is only expressed by pre-
osteoblasts and differentiated osteoblasts [85]. Runx2 is expressed at all phases of 
osteoblastogenesis and is considered the master transcriptional regulator due to its 
upstream expression compared to osterix. Another key factor in osteoblastogenesis is 
peroxisome proliferator activated receptor gamma (Ppar-γ), the key regulator in MSC 
differentiation into adipocytes [18]. Therefore, elevated Ppar-γ competes for MSCs 
thereby promoting their lineage allocation to adipocytes which normally corresponds 
with a decrease in osteoblastogenesis [18]. Also of recent interest in osteogenesis is bone 
morphogenic protein-2 (BMP2). Sun and colleagues [87] showed that treatment of rat 
bone marrow derived MSCs with BMP2 enhanced proliferation and induced an altered 
osteogenic phenotype characterized by increased expression ALP, OCN, OPN, and type-
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1 collagen. Furthermore, BMP2 treatment of MSCs increased nuclear accumulation of 
Runx-2, the master regulator of osteogenesis [87]. Statin drugs and some bioactive 
components in foods have been shown to promote osteogenesis [88].  Our lab and others 
have shown that polyphenol-rich foods, such as dried plums and blueberries, promote the 
proliferation stage of osteogenesis through the upregulation of BMP2 and IGF-I which 
leads to increases in Runx2 and Osterix, [48, 79, 89].  
Stage two of osteogenesis is marked by the halt of cell proliferation and ensuing 
start of differentiation [20]. The extracellular matrix in stage two develops through the 
expression of alkaline phosphatase (ALP) and type 1 collagen. Procollagen type I N-
terminal and C-terminal propeptides (PINP and PICP) are produced from the cleavage of 
type I procollagen into type I collagen by N-proteases and C-proteases [90]. Linkhart and 
colleagues [91] demonstrated that circulating serum PINP is directly proportional to 
collagen formation.  
 The third and final stage is marked by the expression of Phex, Ppar-γ, and 
incorporation of osteocalcin (OCN) into the matrix and subsequent mineralization [20]. 
Phex, an osteoblast integral membrane protein, functions to degrade osteopontin, which is 
expressed in phase I and inhibits bone mineralization. Consequently, Phex degradation of 
osteopontin allows for increased bone mineralization [19]. Ppar-γ functions to down-
regulate bone mineralization by inhibiting the expression of ALP and thereby decreasing 
the formation of hydroxyapatite [92]. The end of the formation stage is marked by the 
appearance of osteocytes within the BMU. During formation, osteoblasts can become 
entombed in bone matrix and develop the phenotype consistent with osteocytes [20].  
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The primary characteristic differing between bone modeling and remodeling is the 
uncoupled actions of osteoblasts and osteoclasts in bone modeling. The independent 
actions of osteoblasts and osteoclasts during bone modeling allows for greater influence 
on bone formation without first requiring bone resorption to occur. Bone modeling is the 
prominent process occurring in developing skeletons making it critical in the attainment 
of peak bone mass. Therefore, it stands to reason that factors that promote bone formation 
(e.g., mechanical loading and polyphenol-rich foods) should be considered important 
components of osteoporosis prevention strategies by their ability to enhance the anabolic 
bone modeling state and the subsequent attainment of an optimal peak bone mass. 
Current Treatments in Osteoporosis 
Current FDA-approved pharmaceutical treatments for osteoporosis target either 
anti-resorptive or anabolic mechanisms of action.  Anti-resorptive drugs (e.g. 
bisphosphonates or Denosumab) are the first line of defense and consequently the most 
widely used drugs in the treatment of osteoporosis [93]. A common bisphosphonate, 
Alendronate, exerts its effects in a number of ways including: reducing osteoclast 
differentiation, reducing osteoclast activity, and promoting osteoclast apoptosis [94]. On 
the other hand, Denosumab is a monoclonal antibody which binds RANKL, thereby 
inhibiting osteoclast differentiation and activation. In response to bisphosphonate or 
Denosumab treatment, the resorptive phase of bone remodeling is significantly reduced, 
thereby reducing the rate of bone loss [27].  
Teriparatide is the only approved anabolic treatment option for osteoporosis and it 
acts to promote bone formation as opposed to slowing the rate of bone loss. Teriparatide, 
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a synthetic form of human parathyroid hormone (PTH), functions by increasing 
osteoblast formation while also inhibiting osteoblast apoptosis [26]. This mechanism of 
action affects the reversal and formation phases of bone remodeling, ultimately leading to 
increased bone mineralization. In severe cases, such as individuals who have already 
suffered a hip fracture [95], anabolic agents may be used in combination with anti-
resorptive drugs to effectively target all stages of bone remodeling and yield a synergistic 
effect [27].  
While these drug therapies have shown notable efficacy in fracture risk reduction 
in both non-vertebral and vertebral fracture sites [96], they can be cost prohibitive and 
produce undesirable side effects [28]. Teriparatide is estimated to cost $800 per month 
which is ten to thirty times the cost of anti-resorptive agents and requires a daily self-
administered injection [97].  Moreover, long-term safety of Teriparatide (>24 months) 
has not been established [98]. Anti-resorptive drugs such as bisphosphonates have 
numerous reported side effects, including gastrointestinal distress, musculoskeletal pain, 
hypocalcemia, increased risk of esophageal cancer and atypical femoral fractures [99]. 
Therefore, investigation and development of novel alternatives which are more effective 
is imperative in the prevention and treatment of osteoporosis. 
Exercise and Bone 
Exercise, namely weight-bearing exercise, has long been heralded as a critical 
modifiable lifestyle factor in the prevention of osteoporosis. Exercise has been shown to 
increase peak bone mass while also attenuating age associated bone loss [100]. Largely 
the effectiveness of exercise has been attributed to loading and micro-damage [101]. 
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Other proposed mechanisms for enhanced bone formation associated with exercise 
involve prostaglandin release, increased blood flow, and hormonal alterations [32]. 
Loading and micro-damage is sensed by osteocytes activating the Wnt/β-catenin pathway 
which transmits signals to surface bone cells (i.e., osteoblasts and osteoclasts), thus 
altering bone cell activity [24]. Increased loading stimulates the Wnt/β-catenin pathway 
in osteoblasts and subsequent activation of Runx2. Runx2 promotes osteoblast 
differentiation and consequently increased bone formation. Equally important to the 
magnitude of the load is the frequency of loading [74]. Increased bone formation 
resulting from exercise is supported by Gönül and colleagues who found that treadmill 
running mice resulted in increased wet and dry weights of the femur and tibia while also 
increasing the Zn, Mg, and Ca mineral contents of bones [31]. 
 Recently, some investigators have begun to explore the role of exercise-induced 
changes in MSC populations as a possible mechanism through which exercise improves 
bone quality. Emerging evidence suggests that exercise influences MSC populations and 
their lineage allocation.  For example, Wallace et al., [33] exposed 4 week-old outbred 
female mice (Hsd:ICR) to treadmill running (12m/m for 30 minutes) for either 5 days or 
5 days a week for 4 weeks. The skeletal effects of the 4-week exercise protocol were 
analyzed via µCT and bone marrow cells of mice that exercised for 5 days were subjected 
to fluorescent activated cell sorting (FACS) to characterize the MSC short-term response 
to exercise. µCT showed significant enhancements of the cortical bone and moments of 
area in the ulna, femur, and tibia, but not in the humerus or radius. Additionally, 
trabecular bone was enhanced by treadmill running in the femur and tibia. FACS analysis 
revealed a significant decrease in the MSC population in the femur after the exercise 
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period, but no difference was observed in the humerus. The authors concluded that the 
MSC populations’ ability to differentiate towards osteoblasts may be a better indicator of 
bone adaptation than the external forces caused by exercise.  Marwdziak et al. [34] also 
examined the effects of treadmill running on MSC populations using 4 week-old male 
C57Bl/6 mice. Mice were subjected to treadmill running for 5 weeks after which MSC 
populations of the tibia and femur were quantified using FACS. The exercised animals 
had a significantly higher population of bone marrow derived MSCs. Additionally, the 
authors reported elevated alkaline phosphatase activity, increased osteopontin and 
osteocalcin in cultured bone marrow derived MSCs, and decreased marrow cavity fat in 
response to treadmill running. The authors suggested that the data is indicative of 
exercise's ability to increase the MSC population and promote its osteogenic potential 
while inhibiting its adipogenic potential. Taken together, these two studies suggest that 
exercise influences the lineage progression of MSCs towards osteoblasts. However, the 
studies differ on the effects of exercise on MSC populations which may indicate that the 
decreased in MSCs observed by Wallace and colleagues [33] was a transient response to 
exercise while the results reported by Marwdziak et al [34] were an adaptive response to 
a prolonged exercise regimen. Although questions remain about the long-term effects of 
exercise on MSCs, these findings suggest that a chronic exercise regimen results in an 
increase in MSCs and osteogenesis making it an important component of strategies 
designed to increase peak bone mass. 
Biomechanical Properties 
 Bone’s ability to withstand stress induced by exercise or other forces may be 
assessed via its biomechanical properties. Bone tissue obtains a rigid structure due to its 
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inorganic mineral content; however, it also possesses elastic properties derived from its 
organic component, largely collagen. Bone’s ability to handle a load is determined by its 
strength, hardness, and type of load [102, 103]. 
 Terminology that is often used to describe bone include bone strength and 
hardness. The strength of bone refers to the maximum sustainable load before failure, 
while the hardness of bone refers to its ability to deform in response to force. Bone is an 
anisotropic material, meaning that depending on the direction of the applied load the 
response can differ. In general, bone possesses a greater capacity to withstand loads in the 
longitudinal direction due in part to the repeated exposure to forces in this direction as a 
result of gravity. [102]. Additionally, bone possesses viscoelastic characteristics, meaning 
it responds to loads differently based on the speed and duration at which they are applied.  
Bone tissue can handle higher loads when delivered fast [103]. This is due to the bone’s 
ability to deform when a load is first applied, known as the elastic response. However, a 
load which is applied continually, exhausts this initial ability of bone to deform, which is 
known as the plastic response, and thus requires significantly less force to result in micro 
damage or fracture [103]. Therefore, bone is most able to withstand a high magnitude 
force which is administered quickly and in the longitudinal direction.  
 An important determinant in the bone’s ability to handle a load is the type of the 
load. Types of load include: compression, tension, shear, torsion, and bending (Figure 7) 





Figure 7: Types of Biomechanical Loads. 
It is characterized by forces pressing simultaneously against opposite sides of the same 
bone [103]. Compressive force results in shortening of the bone in the plane of the 
applied force and extension of the bone in the perpendicular plane (i.e. shorter and 
thicker). Tensive stresses are opposite compressive stresses and are usually caused by 
muscles-tendon actions of pulling on the bone. Exposure to tensive forces causes the 
bone to elongate and narrow [103]. Shear forces occur when a bone is exposed to 
compressive or tensive forces which possess force that is also applied in the horizontal 
plane [102]. The bone fails quickly under shear forces due to anisotropic properties. 
Classically, shear forces cause issues in vertebral discs and femoral condyles [103]. 
Torsion of the bone is indicative of force being applied in a rotational manner. Torsion of 
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the bone (e.g. during exercise) produces shear, compressive, and tensive forces. Lastly, 
bending is a type of deformation that bone undergoes when a force is applied in a 
direction that doesn’t have support offered by the bone’s structure. Bending results in 
tensive and compressive stresses [103]. Ultimately, the bone mass or BMC, protein 
content, and micro-architectural phenotype (e.g. trabecular meshwork and cortical 
thickness) determine a bone’s strength and hardness and consequently determine the 
magnitude, duration, and type of force tolerable. The greater the force a bone can endure, 
the less likely it is to fracture. Therefore, developing and maintaining an optimal BMC, 
protein content, and micro-architectural phenotype is critical in fracture prevention. 
Nutrition and Bone Overview 
Another critical factor in bone health and consequently the development of a high 
peak bone mass is nutrition. Proper bone development requires adequacy of key nutrients 
including vitamin D, calcium, phosphorus, vitamin K, and protein [104]. Bone 
hydroxyapatite is composed of calcium and phosphorus. Therefore, nutritional adequacy 
of the divalent cation calcium and phosphorus is critical in bone mineralization and the 
development of a high peak BM. Estimates suggest that between 60-70% of teenage girls 
and 70% of postmenopausal women consume less than the recommended amount of 
calcium [105].  Calcium absorption and excretion is a tightly regulated process 
modulated by PTH, calcitonin, vitamin D, and the renal system. In response to low blood 
calcium concentrations, the parathyroid gland secretes parathyroid hormone (PTH). PTH 
functions to stimulate resorption of Ca from bone, increase renal reabsorption, increase 
intestinal absorption, and increase 1,25-dihydroxy vitamin D synthesis [106]. Osteoclasts, 
which lack PTH receptors, are indirectly activated by PTH. Pre-osteoblasts possess PTH 
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receptors, which when activated promote their differentiation into osteoblasts. However, 
upon becoming mature osteoblasts PTH stimulates the secretion of IL-6 and IL-1, which 
in turn stimulate osteoblasts to synthesize CSF and RANKL. The net effect is the 
stimulation of osteoclastogenesis [107]. This increase in the formation of osteoclasts 
leads to enhanced bone resorption that normalizes plasma calcium, inhibits PTH 
synthesis and restores homeostasis. 
The RDA for vitamin D is 600 IU per day for individuals between the ages of 1 
and 70 years. Vitamin D may be acquired through the diet (e.g., dairy and fatty fish); 
however, it is primarily derived through subcutaneous sun exposure. Functions of vitamin 
D include increased intestinal absorption of calcium via TRPV6 and calbindin and 
increased osteoclast activity through the stimulation of RANKL expression in osteoblasts 
[108]. It has been estimated that approximately 70% of children in the United States are 
vitamin D insufficient or deficient [109]. This could have important long-term skeletal 
health consequences since vitamin D is essential in maintaining calcium homeostasis and 
bone formation. 
By mass, one-third of bone is composed of protein [110]. The organic matrix of 
bone is largely made up of collagen, which continually undergoes turnover [9]. Post-
translational modifications (e.g. hydroxylation) and remodeling of amino acids in 
collagen is necessary for crosslinking; however, it results in un-usable fragments protein 
thus increasing protein demand [110].  Inadequate dietary protein intake impairs IGF-1 
production. IGF-1 is critical for longitudinal growth of bones as it promotes chondrocytes 
within the growth plates to proliferate as well as the activity of osteoblasts [111]. A study 
by Glick and colleagues [112] showed that chronic protein deficiency did not alter 
35 
 
mineral content of bone, but decreased the quantity of bone formed by significantly 
decreasing appositional bone growth in growing animals [112]. Therefore, an adequate 
supply of protein is necessary for proper collagen formation, IGF-1 production, and 
osteoblast activity. Furthermore, protein is even more critical due to its role in 
longitudinal bone growth in the growing skeleton. 
 Vitamin K, a fat-soluble vitamin, may be consumed in the diet as phylloquinone 
or synthesized endogenously by intestinal bacteria as menanquinone.  Gamma glutamyl 
carboxylase (GGC) is a vitamin K-dependent enzyme that is involved in the 
carboxylation of the bone extracellular matrix protein, osteocalcin [113]. Osteocalcin can 
be found in carboxylated or un-carboxylated form. Carboxylated osteocalcin, the active 
form, promotes bone mineralization.  Thus, low vitamin K intake resulting in 
undercarboxylated osteocalcin correlates with low BMD [114].  
Emerging evidence suggests that the modulating effects of some foods may in 
part be due to non-digestible carbohydrates such as fructooligosaccharides and 
galactooligosaccharides. Non-digestible carbohydrates elicit a number of favorable 
effects, including the promotion of beneficial bacteria (e.g. Bifidobacterium), a reduction 
of pathogenic bacteria, and enhanced short chain fatty acid production (SCFAs) [50]. 
Oligosaccharides have been shown to increase cecal concentrations of SCFAs including 
acetate, propionate, and butyrate [115]. Recently Lucas and colleagues [51] showed that 
SCFAs (i.e. propionate and butyrate) significantly increase bone mass and prevent bone 
loss occurring post-menopause or resulting from inflammation. These researchers suggest 
these effects are exerted via a downregulation of the osteoclastogenesis genes TRAF6 
and NFATc1 [51]. SCFAs are known to modulate the gut mucosal immune responses by 
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increasing T helper cells, macrophages, and neutrophils thereby increasing immune 
function.  Furthermore, SCFAs have pre-biotic effects that can promote calcium 
absorption and increase BMD [116].  
Nutritional adequacy of vitamin D, vitamin K, calcium, non-digestible 
carbohydrates, and protein are critical to the attainment of an optimal peak bone mass 
that can ultimately reduce the risk of osteoporosis. Nutrition also plays a role in bone 
health beyond macro and micro-nutrients. This role is evident when studying how the 
consumption of many plant-based foods affects bone loss and metabolism.  
Functional Foods and Bone 
 Many fruits and vegetables are considered functional foods, which are defined as 
foods with health benefits beyond that which can be attributed to their nutrient 
components [117]. While functional foods can provide macronutrients and micronutrients 
that contribute nutritional adequacy and bone growth, they also contain bioactive 
compounds regarded as phytochemicals. The largest subclass of phytochemicals are the 
polyphenols [118]. Polyphenols may be the pigments in foods as well as the compounds 
that provide flavor, odor, and oxidative stability [118]. Over 8000 polyphenolic 
compounds have been identified and may be further classified as phenolic acids, 
stilbenes, lignans, and flavonoids based on the number of phenol rings, side groups (e.g. 





Figure 8: Chemical structures of polyphenols subclasses [84]. 
 
Characteristically, polyphenols possess potent anti-inflammatory and anti-oxidant 
capacities providing defense against ultraviolet radiation, pathogens, and other 
inflammation causing processes. Polyphenols exert their anti-oxidant capacity in a 
number of ways. Foremost, polyphenols quench free radicals via redox reactions, 
donating an electron and thereby reducing reactive species.  Polyphenols may also 
function as metal chelators, chelating metals such as ferrous iron and thus reducing the 
rate of the Fenton reaction and its production of hydroxyl radicals [119]. Indirectly 
polyphenols may exert antioxidant effects by regenerating antioxidant vitamins (e.g. 
vitamin E) or promoting the synthesis of endogenous antioxidants such as glutathione 
peroxidase, catalase, and superoxide dismutase [120, 121]. Consequently, many studies 
support the efficacy of polyphenols in the attenuation or prevention of chronic diseases 
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(e.g., obesity, cardiovascular disease, Alzheimer’s disease, cancer, diabetes, and 
osteoporosis) in which inflammatory processes are central to the pathophysiology [36, 
121-124]. In particular, a number of studies using cell culture systems, animal models, 
and clinical trial protocols have shown the efficacy of foods with high polyphenolic 
profiles in the prevention or attenuation of osteoporosis. These functional foods include 
dried plums, green tea, soy, and blueberries to name a few.  
A common fruit with a high flavonoid content is blueberries. Blueberries contain 
hippuric acid, phenylacetic acid, and hydoxybenzoic acid [125]. Using an in vitro model, 
Chen and colleagues showed that blueberry polyphenols stimulated Wnt signaling and 
subsequently the differentiation of osteoblast precursors into osteoblasts [126]. In 
ovariectomized rats, blueberry supplementation was found to prevent osteoblast apoptosis 
and the loss of collagen [127]. These results were supported further by Tao and 
colleagues who reported that blueberry prevented the development of osteoporosis in 
ovariectomized rats by inhibiting bone resorption and maintaining trabecular bone 
structure [128].  
Soy and green tea flavonoids have shown marked benefit in the pathophysiology 
of osteoporosis. Studies have shown that soy isoflavones attenuate decreases in tibial 
BMD and BMC in ovariectomized rats, while improving architectural properties 
including trabecular thickness, separation, and number [44]. Furthermore, soy studies 
show significant increases in serum bone formation markers BSAP, IGF-1, and 
osteocalcin [129]. Soy isoflavones are classified as phytoestrogens and are able to bind 
estrogen receptors, eliciting estrogen-like effects (e.g. anti-resorptive), stimulate 
osteoblast activity via IGF-1 synthesis, and downregulate inflammatory cytokines (e.g. 
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TNF- α ) [130-132].  By comparison, the primary phytochemicals in green tea are 
catechin derivatives such as gallocatechin, catechin gallate, gallocatechin gallate, 
epicatechin, epigallocatechin, epicatechin gallate, and epigallocatechin gallate (EGCG) 
with small amounts of phenolic acids (e.g. hydroxybenzoic and hydroxycinnamic acids) 
[133]. Isolated human osteoblasts subjected to oxidative stress and green tea extract 
showed improved mineralization and cell viability while also increasing expression of 
osteocalcin and type I collagen [134]. Long-term supplementation of EGCG exhibits an 
increase in the expression of osteogenic genes (e.g. Runx2) promoting MSC commitment 
to an osteoblast lineage [135]. These findings suggest that green tea, blueberries, and soy 
possess promising therapeutic potential in osteoporosis prevention. 
 Dried plums are a rich source of polyphenolic compounds (e.g., chlorogenic acid, 
caffeoylquinic acids, and quercetin) and non-digestible carbohydrates [136]. Rendina et 
al., [39] examined the effects of diets supplemented with 25% (w/w) of either dried plum, 
apricot, mango, or grapes on bone loss in ovariectomized C57BL/6 mice. Dried plum 
exhibited a unique capability to decrease osteoclastogenesis while increasing osteoblast 
and glutathione activity [39]. Franklin et al., [137] in an animal model using Sprague-
Dawley rats reported that dried plum decreased osteoclastogenesis via the 
downregulation of RANKL expression and promoted bone formation via IGF-1 [138]. 
Using aged male mice, Halloran and colleagues [139] showed that dried plum 
supplementation results in an anabolic effect, causing increased bone volume and 
restoration of bone previously lost to aging. In the growing skeleton, Shahnazari and 
colleagues [140] found that dried plum increased peak bone mass by as much as 94%. 
These animal studies suggest dried plum decreases bone resorption and actually promotes 
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an anabolic effect on bone. Clinical studies on postmenopausal women by Hooshmand et 
al. [37, 141] show that dried plum attenuates bone loss, maintains BMD, and decreases 
serum resorption markers BAP and TRAP-5b. These clinical findings indicate the results 
of the animal studies translate to humans, suggesting that dried plum decreases bone 
resorption and promotes bone formation through the regulation of osteoclast 
differentiation and osteoblast activity. 
 The beneficial effects of functional foods are largely attributable to their 
polyphenolic content. In an in vitro model Bu and colleagues [79, 80] showed that 
isolated plum polyphenols decreased the effects of TNF-alpha on osteoblasts resulting in 
an up-regulation of Runx2, Osterix and IGF1 as well as inhibiting osteoclastogenesis via 
the downregulation of NFATC1 and inflammatory cytokines. Recently, Graef and 
colleagues [47, 48, 142] further demonstrated the ability of select polyphenols to 
independently modulate the activity of osteoblasts and osteoclasts. Bone-marrow derived 
osteoblast cultures treated with one of two crude polyphenolic fractions (i.e. DP-FrA or 
DP-FrB) showed that both fractions increased BMP2 and Runx2 expression [48]. 
Furthermore, treatment of osteoblast cultures with TNF-α, to elicit inflammatory 
conditions, resulted in increased Smad6 and suppressed ALP levels [48]. However, 
treatment with dried plum fractions resulted in an attenuation of this response. Treatment 
of bone-marrow derived osteoclast cultures with polyphenolic fractions (i.e. DP-FrE or 
DP-FrF) produced a decrease in osteoclast differentiation and activity via a 
downregulation of Nfatc1, osteoclast-associated receptor (Oscar), signaling regulatory 
protein β1 (Sirpb1), triggering receptor expressed on myeloid cells 2 (Trem2), 
extracellular signal-regulated kinase (Erk), and p38 MAPK [47]. Under inflammatory 
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conditions (i.e. TNF-α) only Sirpb1 was suppressed via polyphenolic fractions [47]. 
Graef and colleagues [142], further showed these results through translation into an 
animal model using osteopenic Sprague Dawley rats supplemented with dried plum 
polyphenolic extracts alone and in combination with vitamin K. Supplementation with 
the polyphenolic fractions, the combination of the polyphenolic fractions with vitamin K, 
and dried plum all restored whole body BMD to a similar extent. Trabecular bone loss in 
the vertebrae and cortical bone loss in the femur mid-diaphysis was reversed via the 
combination treatment [142]. Biomarkers of bone resorption (i.e. deoxypyridinoline, 
Dpd) were decreased by the fractions and combination treatment [142]. These outcomes 
reinforce the concept that some of these functional foods exert their favorable effects 
largely through their polyphenolic content, but that their fructooligosaccharides may also 
be a contributing factor. 
Tart Cherries  
  Tart cherries are a well-known source of polyphenolic compounds, namely 
hydroxycinnamic acids and anthocyanins, and oligosaccharides (e.g., 
fructooligosaccharides and galactooligosaccharides) [143, 144].  Balaton cherries have 
the highest total anthocyanins while the Montmorency tart cherries are highest in total 
phenolics (Table #2) [143]. These phenolics include anthocyanins (e.g. cyanidins and 
pelargonidins), hydroxycinnamates (e.g. neochlorogenic acid and p-coumaroylquinic 




Table 2: Anthocyanins and total phenolics of tart cherry products [143]. Total 
anthocyanins presented as µg/g dry weight of cyaniding 3-glucoside equivalents. Total 
phenolics presented as µg/g dry weight of gallic acid equivalents.  
 
Tart cherries contain approximately 0.33 g of total fructooligosacharides per 100 g of tart 
cherry [49]. Previous studies suggest that tart cherry supplementation has favorable 
effects on muscle recovery, peripheral neuropathy, and arterial stiffness [145-147]. 
Levers and colleagues [148] reported that tart cherry supplementation increased 
performance in endurance athletes while attenuating muscle catabolism and inflammatory 
stress [148]. Similarly, this same group of investigators found that tart cherry 
supplementation reduced muscle catabolism and soreness during recovery from 
resistance training [149]. Moreover, tart cherry supplementation has been shown to aid in 
muscle recovery following strenuous activity by reducing inflammation and lipid 
peroxidation, and increasing antioxidant capacity [150].  
Due to their rich source of phenolic acids and fructooligosaccharides, our lab 
recently showed that Montmorency tart cherries attenuate age-related bone loss in an 
animal model (manuscript under review). Further investigation showed that Phex gene 
expression was increased and Ppar-γ gene expression was decreased in the groups receiving 
cherry. Taken together these results suggest that tart cherry may in fact promote bone 
mineralization.  Furthermore, at some skeletal sites tart cherry may have an anabolic 
effect on bone. To date no studies have been conducted on tart cherry on the growing 
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skeleton to determine if bone mineral content can be increased. Evidence suggesting that 
tart cherry promotes bone mineralization in the aged skeleton provides the rationale for 
using tart cherry as a means of increasing bone accrual to achieve a higher peak bone 
mass in the growing skeleton.   
Based on this review of the literature, it is clear that osteoporosis is a global health 
concern with increasing prevalence. One of the most important factors in the prevention 
of osteoporosis is the optimization of peak bone mass early in life. Peak bone mass is 
heavily influenced by modifiable lifestyle factors such as diet and exercise. Research 
suggests that functional foods high in anti-inflammatory polyphenols help prevent or 
attenuate osteoporosis. Furthermore, studies conducted on growing animals show that 
polyphenol rich foods increase peak bone mass. Montmorency tart cherries are rich 
sources of these polyphenols and have been shown to have favorable effects on bone in 
the aging skeleton by enhancing mineralization.  Exercise, namely weight-bearing 
exercise, is a well-established lifestyle factor that can enhance peak BM. Therefore, it 
stands to reason that Montmorency tart cherry supplementation is an excellent candidate 
to consider in bolstering peak mass (BMC) in the growing skeleton, and that tart cherries 









Fifty-eight, four-week old female C57BL/6 mice (Jackson Labs) were purchased and 
housed in the OSU Laboratory Animal Research Facility under environmentally 
controlled conditions. Mice were housed 4-5 per cage and underwent a 2-week 
acclimation period during which they were fed a chow diet and acclimated to walking 
and running on a 6-lane treadmill (Columbus Instruments, Columbus Ohio). Next, mice 
were randomly assigned to one of four treatment groups as follows (n=12-14/group) in a 
2x2 experimental design: control diet w/o exercise (Con), control diet + exercise (Con + 
Ex), tart cherry supplemented diet (10% w/w) w/o exercise (TC), and tart cherry 
supplemented diet + exercise (TC + Ex). The control diet was formulated according to 
AIN93-G specifications (Table 2) [151]. Tart cherry powder (Van Drunen Farms, IL) 
was sent to NPAL Analytical Laboratories (St. Louis, Missouri) for protein, fat, fiber, 
calcium, and phosphorus analysis. Diets were adjusted to have similar calcium and 
phosphorus content. Additionally, macronutrients (i.e. protein, fats, and carbohydrates) 
were adjusted to control for macronutrient provided by the addition of tart cherry to the 
experimental diet so that diets were isocaloric.  Food intake was recorded and animals 
had free access to R/O water throughout the study.  Mice were weighed once a week
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Tart Cherry Diet  
(per kg) 
   
Cherry Powder 0 100 
   
Carbohydrates   
Cornstarch (g) 397.5 318.0 
Maltodextrin (g) 132 132 
Sucrose (g) 100 100 
From tart cherry (g) NA 79.5 
Total (g) 629.5 629.5 
   
Protein   
Casein (g) 200 195.5 
From tart cherry (g) NA 4.6 
Total (g) 200 200 
   
Fat   
Soy bean oil (g) 70 69.4 
From tart cherry (g) NA 0.6 
Total (g) 70 70 
   
Fiber   
Cellulose (g) 50 45.7 
From tart cherry (g) NA 4.3 
Total (g) 50 50 
   
Vitamin mix (g) 10 10 
   
Mineral   
Mineral mix (Ca-P Deficient) (g) 13.4 13.4 
Calcium Carbonate (40.04%ca) (g) 12.5 12.4 
Calcium from tart cherry (g) NA 0.045 
Sodium Phosphate, monobasic (25.81% P) (g) 4.2 4.1 
Potassium Phosphate, monobasic (22.76% P)(g) 2.1 2.0 
Phosphorus from tart cherry (g) NA 0.1 
Sucrose (g) 2.8 3 
Total (g) 35.0 35.0 
   
Choline Bitartrate (g) 2.5 2.5 







 Mice in the exercise groups were run 5 days/wk at 12 m/min on a 5° incline for 30 
min. The exercise protocol was typically carried out at approximately 9:00 am to 
minimize interference with diurnal cycles.  Although not required often, mice were gently 
prodded with a tongue depressor if needed to promote compliance with the running 
protocol [152]. Mice in the non-exercising groups were individually removed from cages 
and handled on exercise days for 5 minutes to control for the stress of handling.  
 After the 8-week treatment period, animals were anesthetized using a 
ketamine/xylazine cocktail at 100 mg and 10 mg per kg body weight. Mice were then 
exsanguinated by the carotid artery. Blood samples were collected and serum was 
separated by centrifugation of whole blood at 4,000 rpm for 20 minutes. Serum was then 
aliquoted and stored at -80º C. Bone samples were obtained and stored accordingly. Bone 
marrow from one femur was flushed with RNA later for gene expression analysis, while 
the other femur was stored in PBS for microarchitectural and biomechanical testing. The 
flushed femur hard tissue was snap frozen in liquid nitrogen for protein and gene 
expression assays. Tibias were both flushed with complete media for FACS analysis. The 
spine was removed and the 5th lumbar vertebrae (L5) was isolated for micro-computed X-
ray tomography (µCT) analysis. Tissues, including the liver, white adipose tissue, uterus, 
and spleen were harvested and weighed. 
BMD Assessment Using DXA 
 Prior to necropsy, whole body DXA scans were performed using GE Medical 
Systems Lunar PixiMus (Madison, WI). These scans were used to determine the whole 
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body bone mineral area (BMA), bone mineral density (BMD), bone mineral content 
(BMC), lean mass, fat mass, and body fat percentage.  
Assessment of Microarchitectural Parameters by µCT 
 Femurs and L5 vertebrae specimens, were stored in PBS, and then scanned using 
µCT (MicroCT40, SCANCO, Switzerland). Both trabecular and cortical bone micro-
architectural analysis were performed on the femur and vertebrae. The trabecular bone 
was analyzed in the distal femur metaphysis and the cortical bone was assessed in the 
femur mid-diaphysis. Femur scans of the distal femur metaphysis were performed at a 
high resolution of 2048 x 2048 pixels and analyzed via evaluation of 125 slices (6 
μm/slice or 0.75 mm volume of interest (VOI)) starting 0.09 mm from the growth plate. 
Cortical analysis was performed by evaluating 30 slices or a 0.18 mm VOI at the mid-
shaft.  
L5 trabecular analysis was performed by analyzing all medium resolution slices 
(1024 x 1024 pixels) starting 10 slice in from each growth plate, approximately 150-175 
slices (12 μm/slice or 60 μm VOI). Vertebral cortical bone analysis was performed by 
evaluating ~100 slices or a 1.2 mm VOI. Trabecular bone evaluation provided the ratio of 
trabecular bone volume to total bone volume (BV/TV), trabecular number (TbN), 
trabecular thickness (TbTh), trabecular spacing (TbSp), structural model index (SMI), 
connectivity density (ConnDens), apparent density, and material density. Cortical 
analysis provided cortical bone porosity, cortical area, medullary area, and cortical 
thickness. Cortical analysis of the femur was performed using a threshold of 260 and a 
sigma and support of 0.8 and 1, respectively. Trabecular analysis of the femur, trabecular 
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analysis of the vertebral body, and cortical analysis of the vertebral body was performed 
using a threshold of 400 and a sigma and support of 0.7 and 1.0, respectively.  
Assessment of Bone Marrow MSC Populations by Flow Cytometry FACS 
 Bone marrow was flushed and pooled from both tibias using complete media 
which included DMEM, 0.1g BSA, 58.44 mg EDTA at the time of necropsy. Samples 
were kept on ice and then centrifuged at 750 g for 5 min at 4° C. Media was then 
aspirated and the red blood cells (RBC) lysed for 7 min (FACS Lysing solution, BD 
Biosciences, San Jose, CA). After RBC were lysed, samples were washed and re-
suspended in complete DMEM media for counting. Cells 2 x 106 were aliquoted to 12 x 
75 mm tubes and re-suspended in 100 µl of stain buffer (Stain Buffer, BD Biosciences, 
San Jose, CA). Samples were then incubated for 30 minutes at room temp with the 
following series of 5 antibodies:  SCA-1, CD105, C-Kit, CD44, and CD90. After 
staining, samples were washed 3 times using ice cold PBS and re-suspended in 350 µl of 
stain buffer for subsequent analysis via a Becton Dickinson FACSCalibur. Cells were 
characterized based on the following cell surface markers: (SCA-1+), (CD105+), (C-Kit+),  
(CD44+), and (CD90+). Analysis was performed using successive sub gating for positive 
markers. Final cell counts expressing positive readings for all 5 markers (SCA-1+, 
CD105+, C-Kit+, CD44+, CD90+) were deemed as mesenchymal stem cells and expressed 
as a percentage of total cells analyzed.  
 
 
Serum Biochemical Markers Analyses 
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 Systemic markers of bone formation and resorption were analyzed via 
commercially available kits. Serum tartrate-resistant acid phosphatase form 5b (TRAcP 
5b), which is secreted by osteoclasts to de-mineralize bone, is a marker of bone 
resorption and was assessed using MouseTRAP Elisa kit (Immuno Diagnostic Systems, 
United Kingdom). The sensitivity of the assay is 0.1 U/L and the inter and intra assay 
variability are <8% and <6.5% respectively. Serum N-terminal propeptide of type I 
procollagen (PINP), a byproduct of collagen formation from procollagen, is a marker of 
bone formation and was assessed using a PINP Elisa kit (Immuno Diagnostic Systems, 
United Kingdom). The sensitivity of the assay is 7 ng/mL and the inter and intra assay 
variability are <10% and <8% respectively. Serum osteocalcin (OCN), which promotes 
bone mineralization, was assessed using a mouse OCN ELISA kit (Immutopics Inc., San 
Clemente, CA). The sensitivity of the assay is 0.4 ng/mL and the inter and intra assay 
variability are <7% and <4% respectively.  
Corticosterone, a glucocorticoid released by the adrenal cortex as part of the stress 
response, was measured via a corticosterone Elisa kit (Immuno Diagnostic Systems, 
United Kingdom) to assess stress resulting from the handling involved with the exercise 
protocol. The sensitivity of the assay is 0.55 ng/mL and the inter and intra assay 
variability are <9% and <7% respectively. All kits were run n=10 samples from each 
group in duplicate and read on a plate reader (Synergy HT, BioTek, Winooski, VT).  
Biomechanical Analyses 
 Femurs were cleaned and stored in phosphate buffered saline (PBS) at 4º Celsius 
until biomechanical analysis via reference point indentation (RPI) (Bio-dent Active Life 
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Scientific, Inc, Santa Barbara, CA). Testing was performed at two sites. The first site was 
the mid-diaphysis, which is primarily composed of cortical bone. The second location 
was the femoral neck which is rich in trabecular bone but also has a thick cortex. Both 
sites were tested using 2 N force, 2 Hz, and 10 cycles. Testing of the diaphysis was 
performed using a BP2 probe while testing of the femoral neck used a BP3 probe.  
 µCT analyses allows for micromechanical finite element (FE) models to be 
constructed by converting bone voxels from the VOI into 8-node brick elements [153]. 
Simulated compression testing was performed on the ROI from the scan of the femur 
metaphysis and vertebral body. Selected apparent mechanical properties included: elastic, 
linear, and isotropic with a Young’s modulus of 10 GPa and a Poisson’s ratio of 0.3 
[154]. FE analyses results were used to compute the apparent stiffness, strains, and 
stresses for a given force. These calculations are indicative of loading characteristics for 
individual elements within the bone.  
RNA Extraction and Quantitative Real-Time PCR 
 RNA extraction was performed on both bone marrow and flushed bones. Whole 
frozen femurs were pulverized using a freezer mill (6770 freezer mill, SPEX, Metuchen, 
NJ).  Trizol reagent (Life Technologies, Carlsbad, CA) was used to isolate total RNA 
from samples. Supernatant was placed into a micro-centrifuge tube containing 
chloroform and incubated prior to centrifugation and subsequent phase separation. The 
aqueous phase was transferred into a micro-centrifuge tube containing isopropanol and 
allowed to precipitate on ice for 30 minutes. Samples were then centrifuged, decanted, 
washed with 75% ETOH, and suspended in DEPC H2O. A Nanodrop spectrophotometer 
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(Rockland, DE) was used to determine the concentration, A260/230, and A260/280 
ratios. RNA quality was further verified via gel electrophoresis.  
 Total RNA (2 µg) was treated with DNase I and then cDNA synthesis was 
performed via reverse transcription (Superscript II, Invitrogen, Carlsbad, CA).  Real-time 
quantitative reverse transcription polymerase chain reaction (qRT-PCR) was performed 
in duplicate using 50 ng of cDNA and SYBR green (Roche, Penzberg, Germany) on the 
PCR machine (7300 Real-Time PCR System, Applied Biosystems, Foster City, CA).  
qRT-PCR used gene specific primers to investigate how treatments affected regulators of 
osteoblast differentiation (i.e. Runx2 and Osterix), regulators of osteoclast differentiation 
(i.e. RANKL, NFATC1, and OPG), indicators of bone formation (i.e. Col1al), indicators 
of osteoblast activity and mineralization (i.e. ALP, Phex, and Ppar-γ), and indicators of 
osteoclast activity (i.e. CathK). Primers were validated by performing qRT-PCR using a 
serial dilution of cDNA synthesized from tissue that abundantly expresses the gene of 
interest. The comparative cycle number at threshold (Ct) and the invariant control 
hypoxanthine phosphoribosyltransferase 1 (HPRT1) were used to evaluate the results. 
 
Table 4: Primer Sequence List for qRT-PCR 
Symbol Name Sequence 
RUNX2 Runt-related transcription factor 2 
QF 5′- GGC GTC AAA CAG CCT CTT CA -3′ 
QR 5′- GCT CGG ATC CCA AAA GAA GTT -3′ 
 
Osterix Osterix QF 5’- GAA GTT CAC CTG CCT GCT CTG T-3’ 
QR 5’- CGT GGG TGC GCT GAT GT-3’ 
 
RANKL Receptor activator for nuclear 
factor κ B ligand 
QF 5′- TTT CAA GGG GCC GTG CAA AG -3′ 




NFATC1 Nuclear factor of activated T-cells 
cytoplasmic 1 
QF 5′- TGC AGC TAC ATG GTT ACT TGG AA -3′ 
QR 5′- CGT CAG CCG TCC CAA TG -3′ 
 
ALP Alkaline Phosphatase 
QF 5′- GCA CAA CAT CAA GGA CAT CG -3′ 
QR 5′- TGG CCT TCT CAT CCA GTT CA -3′ 
 
OPG Osteoprotegrin 
QF 5′- GTT CTT GCA CAG CTT CAC CA -3′ 
QR 5′- AAA CAG CCC AGT GAC CAT TC -3′ 
 
Col1al Type 1 collagen 
QF 5′- AGA TTG AGA ACA TCC GCA GCC -3′ 
QR 5′- TCC AGT ACT CTC CGC TCT TCC A -3′ 
 
CTSK Cathepsin K QF 5’- GCA GGA TGT GGG TGT TCA AGT -3’ 
QR 5’- TCC GGA GAC AGA GCA AAG CT -3’ 
 
PHEX Phosphate Regulating 
Endopeptidase Homolog, X-
Linked 
QF 5’ – CTA ACC ACC CAC TCC CAC TT -3’ 
QR 5’ – CCA ATA GAC TCC AAA CCT GAA GA -3’ 
PPAR-λ Peroxisome proliferator-activated 
receptor- λ 
QF 5’ – GAA GCA GAA ACA GGG AGC AC -3’ 
QR 5’ – TGC AGC GGC CGC TAC CAG AGT CGG CAA GAA TC -3’ 
HPRT1  Hypoxanthine 
Phosphoribosyltransferase 1 
QF 5’ – GCC TAA GAT GAG CGC AAG TTG -3’ 
QR 5’ – TAC TAG GCA GAT GGC CAC AGG -3’ 
BMP2 Bone Morphogenic Protein 2 
QF 5' – GGA CAT CCG CTC CAC AAA -3’ 
QR 5' – GGC GCT TCC GCT GTT T – 3’ 
c-Fos Fos proto-oncogene QF 5' – GGA CAG CCT TTC CTA CTA CCA TTC C – 3’ 
QR 5' – AAA GTT GGC ACT AGA GAC GGA CAG A – 3’ 
 
c-Fms Colony Stimulating Factor 1 
Receptor 
QF 5’ – CCT CCT CTG GTC CTG CTG CTG G – 3’ 
QR 5’ – GCT CAC ACA TCG CAG GGT CAC C – 3’ 
TRAF6 TNF receptor associated factor 6 
QF 5’ – CAG CAG TGT AAC GGG ATC TAC – 3’ 
QR 5’ – CTG TGT AGA ATC CAG GGC TAT G – 3’ 
BMP4 Bone Morphogenic Protein 4 QF 5' – TTA TGA GGT TAT GAA GCC CCC A – 3’ 
QR 5' – GCT CAC ATC GAA AGT TTC CCA C – 3’ 
 
RANK Receptor activator for nuclear 
factor κ B 
QF 5' – GCG TGC TGC TCG TTC CA – 3’ 
QR 5' – ATG CCT CTC CTG GGT GCA T – 3’ 
 
OPN Osteopontin QF 5' – ACT CCA ATC GTC CCT ACA GTC G – 3’ 
QR 5' – TGA GGT CCT CAT CTG TGG CAT – 3’ 
 
OCN Osteocalcin QF 5' – TGA GCT TAA CCC TGC TTG TGA CGA – 3’ 
QR 5' – AGG GCA GCA CAG GTC CTA AAT AGT – 3’ 
 
BSP Bone sialoprotein 
QF 5’ – ACA CCC CAA GCA CAG ACT TTT G – 3’ 
QR 5’ – TCC TCG TCG CTT TCC TTC ACT – 3’ 
Sost Sclerostin QF 5' – ACC GGG CGG AGA ATG G – 3’ 




SOD1 Super oxide dismutase-1 QF 5' – GCC CGG CGG ATG AAG A – 3’ 
QR 5' – CGT CCT TTC CAG CAG TCA CA – 3’ 
 
Gpx1 Glutathione peroxidase-1 QF 5' – CGG TTT CCC GTG CAA TC – 3’ 




 All data were analyzed using statistical analysis software version 9.4 (SAS 
Institute, NC). First a Shapiro Wilks test was run to assess whether data was normally 
distributed. Normally distributed data were analyzed for treatment main effects and 
interactions using a two-way ANOVA with diet and exercise as factors. Fischer’s least 
square means was run as a post hoc analysis when F values were significant. Data was 








Body Weight, Tissue Weight, Body Composition, and Food Intake 
Food consumption by all treatment groups gradually increased throughout the 
study, but no significant differences were observed between groups in food intake (~2.7 
g/mouse/d). Although there were no significant differences in body weight at baseline, 
final body weights of the exercising groups were lower (P<0.05) than the non-exercising 
groups (Table 5). Assessment of body composition via x-ray absorptiometry revealed 
that the differences in body weight were a result of a significant reduction in body fat 
mass in response to the exercise protocol (Table 5). However, no effects of exercise were 
observed on whole body lean mass and tart cherry had no effect on body weight or body 
composition after 8 weeks of intervention. 
The effect of tart cherry and exercise on organ weights were determined at the end 
of the study and were expressed per g body weight.  No effects of tart cherry or exercise 
were observed on the heart, liver, spleen, thymus, or uterine weights (Table 5).  An 
exercise effect was exhibited on visceral WAT, resulting in a decrease in tissue weight 
and was consistent with the observed changes in body composition. 
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Whole Body and Femur Bone Mineral Area, Content and Density  
BMD, BMC and BMA were assessed via DXA for the whole body and the femur. 
At the end of the 8-week treatment period, no effects of tart cherry or exercise were 
observed on whole body BMD or femur BMD (Table 6). However, a significant interaction 
was detected in whole body BMC and BMA. Mice fed the control diet exhibited an increase 
in whole body BMA with exercise, while mice consuming the tart cherry diet experienced 
a decrease in BMA. Whole body BMC was significantly elevated compared to Con in the 
TC group, however when combined with exercise the TC/Ex group was not different from 
Con. The TC group increased (P<0.05) whole body BMC and BMA compared to the Con 
group. Site-specific DXA of the femur showed a decrease in BMC and BMA in response 
to exercise (Table 6), but no effect of tart cherry or exercise were observed on femur length, 
suggesting that neither intervention alone or in combination altered bone growth.   
 
Microarchitectural Properties of Femur and Vertebra 
 Morphometric (i.e. BVTV, TbN, TbTh, and TbSp) and non-morphometric 
parameters (i.e. SMI, apparent density, material density, and degree of anisotropy) of 
trabecular bone at the distal femur metaphysis were assessed using µCT as an indicator of 
treatments at a weight-bearing site. An effect of TC and exercise, resulted in an increase 
(P<0.05) in trabecular BVTV was observed in the femur (Table 7). The relative increase 
in femoral BVTV in TC/Ex compared to Con was ~34%. The increase in femoral 
trabecular bone was a result of tart cherry increasing (P<0.05) TbN and TbTh, and 
decreasing TbSp (P<0.05) (Table 7). Analyses of non-morphometric parameters of 
trabecular bone exhibited predominantly a diet effect in the femur metaphysis. The 
trabecular bone had a more plate-like structure resulting from exercise and TC as 
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indicated by the significant decrease in SMI (Table 7). Apparent density of the bone, 
increased in response to tart cherry. Material density of the trabecular bone, which unlike 
apparent density accounts for porosity, was increased in response to TC at this site. The 
degree of anisotropy exhibited no diet or exercise effects. 
  Analysis of the morphometric and non-morphometric parameters of trabecular 
bone micro-architecture in the lumbar vertebral body were also performed using µCT. 
Vertebral BVTV was increased by both tart cherry and exercise (Table 8). The relative 
increase in vertebral BVTV in TC/Ex compared to Con was ~26.6%. In the vertebral 
body, the increase in trabecular bone resulted from a TC and exercise main effects which 
improved TbTh (P<0.05) (Table 8).  However, the effect of exercise on TbTh was 
blunted in the context of the tart cherry diet.  Tart cherry tended to increase TbN 
(P=0.07) and decrease TbSp (P=0.08). Analysis of non-morphometric parameters 
revealed both tart cherry and exercise affect the vertebral body. SMI was decreased by 
tart cherry and exercise (P<0.05) resulting in a more plate-like structure (Table 8). 
Vertebral apparent density increased in response to exercise and to tart cherry, but no 
differences in the trabecular bone material density was detected. Similar to the femur, the 
degree of anisotropy in the vertebral body exhibited no diet or exercise effects. 
 Cortical analysis at the femur mid-diaphysis and vertebral cortex resulted in 
distinctly different responses to treatment. No effect of tart cherry or exercise was 
detected on cortical thickness in the mid-femur diaphysis, but an exercise effect resulting 
in a decrease in cortical area was observed (Table 7). However, no effects of treatments 
were observed on cortical bone porosity or medullary area (Table 7). The only cortical 
parameter generally reported for the vertebral body, cortical thickness, was increased by 
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tart cherry, exercise, and exhibited a trend toward an interaction (P=0.06). The effects of 
treatment in the TC/Ex group resulted in a 16.13% increase in vertebral cortical thickness 
compared to Con.  
 Taken together these data indicate tart cherry improved trabecular bone micro-
architecture in both the femur and spine as well as enhanced cortical bone thickness in 
the spine.  
 
Femur and Vertebral Biomechanical Testing 
Finite element analysis was performed to assess trabecular bone biomechanical 
properties in the femur metaphysis and vertebral body via simulated compression testing. 
According to the results of these tests, tart cherry improved all of the trabecular bone 
biomechanical properties, including stiffness, total force, size independent stiffness, and 
corrected Von Mises, in the femur and vertebral body (Table 9).  Additionally, favorable 
exercise effects were observed on all trabecular bone biomechanical parameter in the 
vertebral body, but improved biomechanical properties did not reach of the level of 
statistical significance in the femur metaphysis (Table 9). Enhanced bone strength in the 
TC/Ex compared to control was evident by a 101.43% and a 59.86% increase in total 
force required to fracture in the femur and vertebral body, respectively. Furthermore, 
average Von Mises, a measure of material stress under an established force, for TC/Ex 
decreased compared to Con by 45.07% and 29.82% in the femur and vertebral body, 
respectively. These data suggest that TC and exercise induce alterations in trabecular 
bone micro-architecture which result in enhanced bone strength. 
In addition to trabecular bone biomechanical testing, reference point indentation 
of the femur mid-diaphysis was used to assess cortical bone biomechanical properties. In 
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agreement with the effects of treatments on cortical microarchitecture, no effect of tart 
cherry or exercise was observed on total indentation distance or indentation distance 
increase (Table 10). However, tart cherry tended to decrease (P=0.08) total indentation 
distance, which would be consistent with a stronger bone structure. Reference point 
indentation testing was also performed at the femoral neck, a trabecular rich site with a 
thick outer cortex, and exhibited profound effects. A tart cherry, exercise, and interaction 
effect decreased total indentation distance. Relative to Con the Con/Ex group exhibited a 
21.95% decrease in total indentation distance, but this improvement in bone 
biomechanical properties did not occur in the mice consuming the tart cherry diet 
(TC/Ex).  Exercise decreased the indentation distance increase and tart cherry tended 
(p=0.06) to produce a similar effect. Relative to Con the Con/Ex group exhibited a 27.5% 
decrease in indentation distance increase, but this improvement did not occur in mice 
consuming the tart cherry diet (TC/Ex). 
   
FACS Assessment of Mesenchymal Stem Cells 
 Tibial bone marrow derived mesenchymal stem cell populations were assessed via 
FACS utilizing a progressive gating scheme. Sub-gating was performed to identify SCA-
1+, CD90+/CD44+, and CD105+/c-Kit+ cells, which were classified as MSCs (2-1) 
(Figure 9A-C). MSC populations were increased (p=0.001) in response to exercise 
(Figure 9D). Exercise significantly increased the percent MSC with the bone marrow 
(Figure 12).  In contrast, tart cherry tended to decrease the MSC population (p=0.069). 
No interaction effect was observed between tart cherry and exercise; however, an ~25% 
decrease in MSCs in the TC/Ex group was observed in comparison to the Con/Ex group. 
These data indicate that while exercise increases the MSC population, TC inhibits this 
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response, suggesting that either the combination reduces the MSC in bone marrow, or 
promotes their allocation to another lineage. 
 
Serum Corticosterone 
Due to the effects that stress can have on bone metabolism and the need to 
eliminate the possibility that the exercise regimen elicited a stress response, serum 
corticosterone was assessed. Interestingly, there was no effect of exercise on serum 
corticosterone, but tart cherry reduced serum levels by 45.18% (Figure 10A). This 
indicates that the exercise protocol did not induce stress exceeding that of non-exercising 
groups, but that supplementing the diet with TC effectively lowered serum 
corticosterone.  
 
Serum Bone Biomarkers 
Serum OCN and P1NP were assessed to determine the systemic effects of TC and 
exercise on bone formation and turnover. Serum P1NP, which is indicative of type 1 
collagen formation, was decreased in response to TC (P<0.0001) and tended to be 
decreased (P=0.09) in response to exercise (Figure 10B). In contrast, OCN, an indicator 
of bone mineralization, was not altered by either tart cherry or exercise (Figure 10C). 
Serum TRAP5b was assessed to determine the effects of TC and exercise on bone 
resorption. Neither diet nor exercise had a significant effect on serum TRAP (Figure 
10D).   
  
Gene Expression Associated with Osteoblast Differentiation and Activity 
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 The differentiation of MSC into osteoblast is a highly regulated process an 
essential for the bone formation stage of bone remodeling. The relative abundance of the 
primary regulator of osteoblast differentiation, Runx2 was not altered by tart cherry or 
exercise effect was observed (Table 11). Osterix, another key regulator of osteogenesis 
downstream of Runx2, similarly exhibited no diet or exercise effects (Table 11). BMPs 
are important cytokines which function as growth factors and promote osteoblast 
differentiation were also assessed. BMP-2 was significantly increased (80%) by tart 
cherry, but there was no observed effect of exercise (Table 11). BMP-4 was not affected 
by tart cherry or exercise after 8 wks of treatment.   
 The organic matrix of bone is primarily composed of type 1 collagen. Type 1 
collagen is formed through the cleavage of pro-type 1 collagen. qRT-PCR was performed 
to quantify the expressions of type 1 collagen. No tart cherry or exercise effects were 
observed on the expression of Col1a1 (Table 11). These data indicate that TC and Ex did 
not affect the formation of type 1 collagen. Mineralization of bone and resorption of 
minerals is a tightly controlled process that is critical to bone formation. Ppar-λ, which is 
a known inhibitor of bone mineralization, did not exhibit any differences in the femur 
(Table 11). No diet or exercise effects were observed on OPN, which is expressed during 
early stages of bone formation, or Phex, which degrades OPN during later stages to allow 
mineralization (Table 11). OCN and BSP, which stimulate bone mineralization, exhibited 
no changes in expression resulting from treatments (Table 11). These data suggest 




Sclerostin, secreted by osteocytes in response to mechanical unloading, is an 
inhibitor of Wnt signaling and consequently osteoblast bone formation. Exercise or 
mechanical loading suppresses the expression of sclerostin. qRT-PCR was performed to 
quantify the expressions (Table 11). No TC or exercise effects were observed on the 
expression of sclerostin.   
 
Gene Expression Associated with Osteoclast Differentiation and Activity 
 Osteoclastogenesis, or the differentiation of osteoclasts from HSCs, is crucial to 
bone resorption during both bone modeling and remodeling. The relative abundance of 
RNA for signaling molecules (i.e. RANKL and OPG), cell surface receptors (i.e. RANK 
and c-FMS) and signaling cascades (i.e. TRAF6 and c-Fos) that regulate Nfatc1 
expression and in turn osteoclastogenesis were assessed. No diet or exercise effects were 
observed on RANKL, its receptor RANK, or its competitive inhibitor OPG (Table 12). c-
Fms, the receptor for MCSF, did not exhibit a tart cherry main effect or an interaction 
(Table 12). However, exercise tended to decrease c-Fms gene expression (P=0.05) (Table 
12). No effects were observed on TRAF6, but tart cherry tended to decrease the 
expression of c-Fos (P=0.07) in the bone (Table 12). The key regulator of 
osteoclastogenesis, Nfatc1, was significantly downregulated by TC/Ex compared to all 
other groups. Relative to Con, TC/Ex expressed ~36% decreased Nfatc1 expression. 
These data suggest that TC/Ex suppresses osteoclast differentiation locally within the 
femur via a downregulation of Nfatc1 which is mediated by a TC effect on c-Fos and 
exercise’s effect on c-FMS.  
 Resorption of collagen is mediated by cathepsin-K, an osteoclast protease. qRT-
PCR was performed to quantify the expressions of cathepsin-K. No tart cherry or exercise 
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effects were observed on the expression of Ctsk (Table12). These data indicate that TC 
and Ex did not affect the proteolysis of type 1 collagen.   
   
Endogenous Antioxidant Gene Expression 
 Synthesis of endogenous antioxidants (i.e. GPX and SOD) is critical to 
eliminating free radicals. In terms of Gpx1, no main effects of tart cherry or exercise 
were observed (Figure 11A).  However, Gpx1 was significantly increased in the TC 
group relative to control and the addition of exercise suppressed this response. Relative to 
Con, TC elicited a 23% increase in Gpx1 expression. No differences were observed in 


















Body Weights             
Baseline (g) 16.07 + 0.26 16.44 + 0.28 16.49 + 0.26 16.09 + 0.34 0.9173 0.9245 0.1838 
Final (g) 23.28 + 0.27 22.55 + 0.47 23.45 + 0.55 22.18 + 0.53 0.8714 0.0385 0.5696 
Body Composition         
Lean mass (g) 17.73 + 0.26 17.62 + 0.28 18.01 + 0.27 17.24 + 0.29 0.8490 0.1130 0.2393 
Fat mass (g) 5.75 + 0.23 4.60 + 0.23 5.52 + 0.38 5.00 + 0.27 0.7026 0.0055 0.2775 
Percent Fat (%) 24.43 + 0.81 20.58 + 0.66 23.30 + 1.28 22.30 + 0.63 0.6765 0.0094 0.1138 
Tissue Weight          
Heart (mg/g of bw) 4.49 + 0.31 4.71 + 0.32 4.24 + 0.17 4.32 + 0.10 0.1855 0.5289 0.7670 
Liver (mg/g of bw) 47.59 + 0.85 46.29 + 0.93 45.40 + 1.23 46.73 + 1.01 0.4075 0.9687 0.2034 
Spleen (mg/g of bw) 4.52 + 0.12 4.96 + 0.35 4.73 + 0.17 4.32 + 0.12 0.3055 0.9994 0.0516 
Thymus (mg/g of bw) 2.82 + 0.14 2.45 + 0.14 2.50 + 0.16 2.45 + 0.11 0.1033 0.1923 0.3819 
Visceral WAT (mg/g of bw) 27.92 + 2.08 18.97 + 1.41 24.48 + 2.70 21.60 + 1.07 0.9068 0.0037 0.1199 
Uterus (mg/g of bw) 3.20 + 0.39 4.39 + 0.62 3.37 + 0.49 3.09 + 0.31 0.2131 0.3500 0.1237 
Table 5 
 Body Weights, Tissue Weights, and Body Composition. 
Data are presented as mean ± SE. Within a given row, values that share the same superscript letter are not statistically different from each other. Abbreviations: bw body weight; 












Whole Body DXA               
BMD (mg/cm2) 51.95 + 0.5 51.95 + 0.4 52.39 + 0.4 52.29 + 0.3 0.3471 0.9010 0.9083 
BMC (mg) 439.00 + 9.2b 459.46 + 7.95ab 466.68 + 9.06a 448.62 + 5.99ab 0.3240 0.9297 0.0213 
BMA (cm2) 8.45 + 0.17c 8.84 + 0.10ab 8.91 + 0.13a 8.51 + 0.08bc 0.6716 0.8909 0.0026 
Femur DXA         
BMD (mg/cm2) 52.31 + 0.7 52.53 + 0.8 54.41 + 0.6 52.78 + 0.8 0.1047 0.3407 0.2111 
BMC (mg) 23.83 + 0.37 22.92 + 0.40 24.69 + 0.40 23.08 + 0.36 0.1503 0.0019 0.3666 
BMA (cm2) 0.457 + 0.006 0.439 + 0.003 0.455 + 0.004 0.439 + 0.008 0.9820 0.0058 0.8427 
Femur          
Length (mm) 15.01 + 0.14 15.02 + 0.11 15.01 + 0.08 14.76 + 0.12 0.2823 0.2937 0.2755 
Table 6 
 Whole body DXA, Femur DXA, and Femur Length. 
Data are presented as mean ± SE. Within a given row, values that share the same superscript letter are not statistically different from each other. BMD bone mineral density; BMC 













  Distal-Femur Metaphysis        
        BVTV (%) 9.11 + 0.36 10.24 + 0.53 11.71 + 0.23 12.22 + 0.42 <0.0001 0.0462 0.4433 
        Tb.N. (1/mm) 3.91 + 0.07 3.96 + 0.07 4.12 + 0.04 4.26 + 0.08 0.0004 0.1778 0.4928 
        Tb.Th. (mm) 0.045 + 0.001 0.045 + 0.001 0.049 + 0.001 0.047 + 0.001 0.0002 0.6614 0.1634 
        Tb.Sp. (mm) 0.26 + 0.0112 0.25 + 0.0105 0.24 + 0.0091 0.24 + 0.0116 0.0004 0.2202 0.6223 
Connectivity Density (1/mm) 147.11 + 9.16 172.75 + 12.67 186.02 + 9.81 216.05 + 14.30 0.0010 0.0215 0.8519 
        SMI  2.28 + 0.048 2.08 + 0.057 2.00 + 0.034 1.94 + 0.045 <0.0001 0.0083 0.1146 
        Apparent Density (mg HA/ccm) 218.47 + 6.07 231.40 + 7.32 250.04 + 3.27 258.92 + 6.36 <0.0001 0.0737 0.7351 
        Material Density (mg HA/ccm) 1136.49 + 4.29 1140.89 + 3.41 1150.88 + 2.81 1146.28 + 2.78 0.0054 0.9770 0.1898 
        Degree of Anisotropy (%) 1.62 + 0.03 1.64 + 0.02 1.66 + 0.02 1.62 + 0.03 0.6663 0.5610 0.2132 
Mid-Femur Diaphysis           
        Cortical Thickness (mm) 0.201  + 0.002 0.199 + 0.001 0.201 + 0.002 0.200 + 0.001 0.8863 0.2255 0.9053 
        Porosity (%) 0.899 + 0.045 1.007 + 0.048 0.926 + 0.044 0.93 + 0.024 0.5124 0.1925 0.2179 
        Cortical Area (mm2) 0.825 + 0.009 0.809 + 0.007 0.837 + 0.010 0.812 + 0.010 0.3641 0.0249 0.6172 
        Medullary Area (mm2) 7351.3 + 443.9 8347.7 + 383.8 7767.5 + 419.3 7664.6 + 207.5 0.6790 0.2497 0.1474 
Table 7 
Femur Microarchitecture of Trabecular and Cortical Bone Assessed Using μCT 
Data are presented as mean ± SE. Within a given row, values that share the same superscript letter are not statistically different from each other. BV/TV bone volume per unit of 












Vertebral Body         
      BVTV (%) 16.08 + 0.35 18.04 + 0.73 18.76 + 0.54 20.35 + 0.40 <0.0001 0.0015 0.7303 
      Tb.N. (1/mm) 4.46 + 0.075 4.47 + 0.066 4.49 + 0.043 4.64 + 0.045 0.0746 0.1789 0.2460 
      Tb.Th. (mm) 0.045 + 0.001b 0.048 + 0.001a 0.048 + 0.001a 0.048 + 0.001a 0.0178 0.0198 0.0339 
      Tb.Sp. (mm) 0.23 + 0.004 0.22 + 0.004 0.22 + 0.002 0.21 + 0.002 0.0815 0.1094 0.3633 
      Connectivity Density (1/mm) 191.96 + 9.49b 190.86 + 6.18b 204.78 + 7.05b 232.99 + 4.15a 0.0002 0.0653 0.0420 
      SMI 1.55 + 0.034 1.38 + 0.072 1.25 + 0.054 1.14 + 0.045 <0.0001 0.0134 0.5633 
      Apparent Density (mg HA/ccm) 344.02 + 4.28 362.73 + 7.85 371.27 + 6.04 389.40 + 4.63 <0.0001 0.0031 0.9605 
      Material Density (mg HA/ccm) 1137.24 + 2.55 1140.81 + 2.29 1137.05 + 2.26 1134.36 + 2.34 0.1610 0.8327 0.1933 
      Degree of Anisotropy (%) 1.84 + 0.028 1.80 + 0.015 1.80 + 0.025 1.78 + 0.017 0.2332 0.1317 0.7262 
Vertebral Cortex         
        Cortical Thickness (mm) 0.062 + 0.001 0.069 + 0.001 0.069 + 0.001 0.072 + 0.001 <0.0001 <0.0001 0.0606 
Data are presented as mean ± SE. Within a given row, values that share the same superscript letter are not statistically different from each other. BV/TV bone volume per unit of 
tissue volume; Tb.N. trabecular number; Tb.Th. trabecular thickness; Tb.Sp. trabecular separation; Conn Density connectivity density; SMI structural model index. 
Table 8 













Femur Metaphysis FEA        
Stiffness (Nx103/mm) 344.95 + 49.20 474.17 + 73.84 633.27 + 44.63 694.21 + 49.66 <0.0001 0.0938 0.5417 
Total Force (N) 179.49 + 25.36 249.93 + 38.26 329.64 + 23.29 361.54 + 25.86 <0.0001 0.0825 0.5071 
Size Independent Stiffness (N/m) 112.48 + 15.82 155.58 + 23.57 197.97 + 14.14 223.71 + 17.40 0.0001 0.0636 0.6335 
Corrected Von Mises (MPa) 6.59 + 0.88 4.79 + 0.31 3.69 + 0.10 3.62 + 0.19 0.0001 0.0563 0.0778 
Vertebra FEA        
Stiffness (N/mm) 243.66 + 22.47 312.73 + 24.65 345.59 + 34.56 370.50 + 37.05 0.0006 0.0330 0.3113 
Total Force (N) 322.91 + 24.39 431.05 + 30.60 460.66 + 29.93 516.2 + 23.89 0.0002 0.0042 0.3407 
Size Independent Stiffness (N/m) 387.57 + 22.24 514.74 + 36.91 521.99 + 30.93 584.63 + 27.14 0.0012 0.0025 0.2847 
Corrected Von Mises (MPa) 14.62 + 0.64 12.31 + 0.56 11.31 + 0.46 10.26 + 0.28 <0.0001 0.0017 0.2204 
Data are presented as mean ± SE. Within a given row, values that share the same superscript letter are not statistically different from each other. 
Table 9 





Biomechanical Analysis of Cortical Bone in Femur Diaphysis and Femoral Neck Using Reference Point Indentation. 
 
 







Mid Diaphysis                
Total Indentation Distance (µm) 33.1 + 0.83 32.9 + 0.42 31.8 + 0.39 32.4 + 0.39 0.0806 0.7009 0.4344 
Indentation Distance Increase (µm) 5.11 + 0.27 5.41 + 0.23 4.93 + 0.14 4.91 + 0.27 0.1224 0.5580 0.4988 
Femoral Neck          
Total Indentation Distance (µm) 30.62 + 1.15b 23.88 + 0.88a 25.13 + 0.93a 24.88 + 0.52a 0.0183 0.0006 0.0012 
Indentation Distance Increase (µm) 4.4 + 0.29b 3.19 + 0.09a 3.36 + 0.25a 3.39 + 0.16a 0.0555 0.0084 0.0063 




Figure 9. Representative figure of MSC population based on: SCA-1+, CD90+, CD44+, CD105+, and c-Kit+. Events in p11 (A) were identified based on SSC and SCA-1+, events in 
Q2 (B) CD90+/CD44+, and events in Q2-1 (C) CD105+/c-Kit+ indicating them as mesenchymal stem cells. (D) Effects of 60 days of exercise (Ex), tart cherry (TC), or their 
combination on tibial bone marrow derived mesenchymal stem cells (MSC). Bars represent the mean + SE for each treatment group. Bars that share the same superscript letter are 
not significantly (p<0.05) different from each other.  



































Figure 10. Effects of 60 days of exercise (Ex), tart cherry (TC), or their combination on serum markers of stress (i.e. Corticosterone), bone formation (i.e. P1NP and OCN), or 
bone resorption (i.e. TRAP). A) corticosterone; B) P1NP procollagen type 1 amino terminal pro-peptide; C) OCN osteocalcin; D) TRAP tartrate-resistant acid phosphatase. Bars 

























































































































Osteoblastogenesis         
Osterix 1 + 0.16 1.24 + 0.27 0.92 + 0.22 1.35 + 0.50 0.9871 0.3060 0.7597 
RUNX2 1 + 0.16 1.25 + 0.21 1.03 + 0.21 1.06 + 0.31 0.7366 0.5449 0.6380 
BMP2 1 + 0.12 0.92 + 0.17 1.45 + 0.20 2.00 + 0.57 0.0266 0.4787 0.3223 
BMP4 1 + 0.11 0.99 + 0.15 1.08 + 0.21 0.91 + 0.31 0.9505 0.6995 0.6992 
Osteoblast Activity         
Col1a1 1 + 0.16 0.80 + 0.14 1.06 + 0.16 0.90 + 0.29 0.6304 0.3621 0.9329 
Mineralization         
OPN 1 + 0.23 0.82 + 0.13 0.70 + 0.10 0.90 + 0.18 0.5206 0.9857 0.2755 
OCN 1 + 0.13 1.09 + 0.22 0.94 + 0.07 1.09 + 0.29 0.8809 0.5431 0.8897 
BSP 1 + 0.21 0.83 + 0.14 0.97 + 0.11 0.89 + 0.28 0.9359 0.5294 0.8150 
Phex 1 + 0.08 1.49 + 0.22 1.06 + 0.21 1.02 + 0.44 0.3067 0.2088 0.1962 
PPAR-λ 1 + 0.25 0.95 + 0.12 1.22 + 0.22 0.81 + 0.16 0.6224 0.2118 0.2816 
Osteocyte         
Sost 1 + 0.20 1.40 + 0.24 1.06 + 0.25 1.22 + 0.38 0.8411 0.3240 0.6779 
Data are presented as mean ± SE. Within a given row, values that share the same superscript letter are not statistically different from each other. RUNX2 runt related transcription 
factor-2; BMP4 bone morphogenic protein-4; BMP4 bone morphogenic protein-2; OPN osteopontin; OCN osteocalcin; Phex phosphate regulating neutral endopeptidase; PPAR- λ 
peroxisome proliferator activated receptor-gamma; BSP bone sialoprotein; Col1a1 type 1 collagen; Sost sclerostin.  
 
Table 11 
Relative Gene Expression Related to Osteoblastogenesis, Mineralization, Collagen Formation, and Osteocytes. 
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Osteoclastogenesis       
 
Nfatc1 1 + 0.07b 0.93 + 0.07b 1.10 + 0.12b 0.64 + 0.05a 0.0972 0.0075 0.0287 
MCSF 1 + 0.08 1.07 + 0.10 0.71 + 0.06 0.65 + 0.05 0.0002 0.9872 0.3908 
c-Fos 1 + 0.13 1.20 + 0.22 0.76 + 0.17 0.79 + 0.10 0.0707 0.4866 0.6171 
c-Fms 1 + 0.13 0.88 + 0.06 1.35 + 0.19 0.84 + 0.05 0.6249 0.0543 0.2846 
TRAF6 1 + 0.08 0.97 + 0.12 1.07 + 0.14 0.90 + 0.07 0.9932 0.3608 0.5037 
RANK 1 + 0.10 0.95 + 0.06 1.12 + 0.14 0.93 + 0.06 0.7490 0.2452 0.4817 
RANKL 1 + 0.15 0.97 + 0.21 1.18 + 0.12 0.91 + 0.18 0.6709 0.4113 0.4941 
OPG 1 + 0.09 1.39 + 0.24 1.28 + 0.25 1.13 + 0.33 0.9505 0.5840 0.2821 
Activity        
Ctsk 1 + 0.12 1.43 + 0.21 1.64 + 0.29 1.30 + 0.28 0.3170 0.7946 0.1229 
MMP2 1 + 0.15 1.20 + 0.12 0.93 + 0.09 0.70 + 0.07 0.0430 0.9735 0.0993 
MMP3 1 + 0.26 0.47 + 0.13 1.12 + 0.53 0.80 + 0.36 0.4982 0.2615 0.7763 
MMP8 1 + 0.07
a
 1.29 + 0.11
b
 0.94 + 0.05
a
 0.75 + 0.09
a
 0.0023 0.5852 0.0105 
MMP9 1 + 0.04 1.12 + 0.10 0.87 + 0.07 0.70 + 0.08 0.0019 0.7004 0.0688 
Table 12 
Relative Gene Expression Related to Osteoclastogenesis and Collagen Resorption. 
Data are presented as mean ± SE. Within a given row, values that share the same superscript letter are not statistically different from each other. Nfatc1 nuclear factor of activated t-
cells 1; MCSF macrophage colony stimulating factor; c-Fos; c-Fms colony stimulating factor-1 receptor; TRAF6 TNF receptor associated factor-6; RANK receptor activator of 




Figure 11. Effects of 60 days of exercise (Ex), tart cherry (TC), or their combination compared to control on endogenous antioxidant expression. A) Gpx1 glutathione peroxidase-
1; B) SOD1 super-oxide dismutase-1. Bars represent the mean + SE for each treatment group. Bars that share the same superscript letter are not significantly (p<0.05) different 















































































This is the first study to assess the effects of tart cherry alone and in combination 
with exercise on the accrual of bone mass in a model of the growing skeleton. A previous 
study in our lab demonstrated the efficacy of tart cherry (5 and 10%) in the prevention of 
bone loss resulting from aging (manuscript under review). The results of the current 
study demonstrate that tart cherry and exercise exert significant benefit on trabecular and 
cortical bone in the growing skeleton, even though the combination did not elicit a 
synergistic or additive effect on most bone structural or biomechanical parameters. 
Moreover, it is worth noting, the magnitude of the response of bone parameters (e.g. 
whole body BMC, femoral and vertebral trabecular bone volume) was greater in terms of 
tart cherry than the response to exercise.  
 Peak bone mass has been identified as one of the single greatest predictors of 
osteoporosis risk [30]. The bone mass achieved in the growing animals used in this study 
after 8 weeks of treatment, was increased by 6.31% in response to tart cherry as indicated 
by whole body BMC. However, the addition of exercise did not enhance this response. 
Site-specific assessment of BMC in the femur, a site loaded by the treadmill running 
exercise regimen used in the study, suggested that exercise suppressed BMC accrual 
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compared to controls. To better understand the effects of tart cherry and exercise, 
trabecular and cortical bone compartments were assessed utilizing µCT. Trabecular bone 
analysis of the distal femur metaphysis revealed a ~34% increase in trabecular bone 
volume in response to exercise and tart cherry combined. This effect of tart cherry on 
trabecular bone resulted from an increase in both the number and thickness of trabeculae. 
In terms of the cortical bone, the only cortical parameter in the femur that was affected by 
exercise or tart cherry was cortical area, which was reduced by exercise. The reduction in 
cortical area was not anticipated as several studies have reported no alterations in cortical 
area in growing female C57BL/6 mice in response to treadmill running [155-157]. 
Wallace and colleagues [157] utilized a similar exercise protocol as the one used in the 
present study, showed no differences in cortical parameters in either the femur or tibia of 
female mice. This response raised the question of whether or not an exercise-induced 
stress response could be responsible.  However, serum corticosterone was not altered by 
exercise in this study.  Unexpectedly, trabecular bone of the spine, at a site not directly 
loaded by treadmill running, exhibited a more robust response to exercise and tart cherry 
with a 12.2% and 16.7% increase in BV/TV, respectively.  Synergistic effects of the tart 
cherry and exercise on trabecular bone of the spine were noted and resulted from an 
increase in trabecular thickness resulting in a 26.6% increase in trabecular volume. 
Unlike the cortical bone in the femur, cortical thickness in the vertebrae was improved by 
16.1% from the combination of exercise and tart cherry. It would be expected that 
exercise would more significantly affect the femurs due to increased mechanical loading; 
however, these results suggest a greater effect in the vertebral body.  Data regarding the 
effects of treadmill running on the vertebral body is limited, but Iwamoto and colleagues 
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[158] reported a similar improvement in lumbar bone mass in response to a long-term 
exercise regimen.  This response in the vertebrae could be due to the incline of the 
treadmill or from the forces resulting from flexion involved in running for quadrupedal 
animals, but that cannot be determined for certain from this study. 
To date, no other studies have investigated the effects of tart cherry in the young 
growing skeleton. However, dried plum, which has a similar polyphenolic and 
oligosaccharide composition as tart cherry, has been investigated in the growing skeleton. 
Shahnazari and colleagues [140] reported that 5%, 15%, and 25% dried plum 
supplementation in growing male mice resulted in 12%, 36%, and 64% increases in 
trabecular bone volume, respectively. Chen and colleagues [126] reported that blueberry 
supplementation (10% w/w), which is also a rich source of polyphenolic compounds, 
resulted in a ~30% increase in tibial trabecular bone volume in growing female rats. By 
comparison, 10% tart cherry supplementation resulted in a ~28.5% increase in femoral 
trabecular bone volume. Zhu and colleagues [159] reported that in growing male 
mice trabecular bone volume was 3-fold higher in alendronate-treated mice, 2-fold higher 
in Zoledronate-treated mice, and 1.3- to 1.6-fold higher in Clodronate- and Pamidronate-
treated mice. In terms of trabecular bone volume, tart cherry had comparable effects to 
dried plum, blueberry, and Pamidronate; however, unlike bisphosphonates, tart cherry 
elicited no unfavorable side effects and amounts to a fraction of the cost. 
 As a result of the alterations in bone structural properties, the effects of tart cherry 
and exercise were examined on bone biomechanical properties. Finite element analysis of 
trabecular bone within the distal femur revealed a 101.4% increase in the total force in 
the group receiving the tart cherry and exercise compared to the control group.  Both 
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exercise and tart cherry improved the structural model index, which likely contributes to 
this response. Tart cherry alone improved stiffness and Von Mises stresses at this site and 
the effects of exercise only tended to have favorable effects. Similar to our observations 
in the structural parameters of trabecular bone within the spine, there was a robust 
response in non-morphometric parameters to exercise compared to the femur. The 
vertebral body exhibited a more plate like structure and increased apparent density in 
response to tart cherry and exercise alone. Trabecular bone strength was markedly 
improved with an ~60% increase in total force exhibited by the mice treated with the 
combination of tart cherry and exercise. Despite the more robust bone structural change 
in the spine, the effects on the trabecular bone biomechanical properties were not as great 
as those observed in the femur. Evaluation of cortical bone biomechanical parameters in 
the femur utilizing reference point indentation testing revealed no effects on bone 
biomechanical properties indicating that any structural changes that did occur in the 
femur, did not affect cortical bone strength. However, in the femoral neck a trabecular 
rich site with a thick cortex, total indentation distance was decreased suggesting a 
positive response to tart cherry, exercise, and their combination. A previous study 
examining the effects of treadmill running (15m/m for 30 min 5 d/wk) on bone 
biomechanical properties resulted in no alterations in stiffness or bearable load in 8 week 
old male C57BL/6 mice [160].  However, no studies on the effects of tart cherry on bone 
biomechanical have been published to date. The effects of other functional foods have 
revealed improvements in bone biomechanical properties  soy protein, flaxseed, and their 
combination in young growing animals [161]. Our findings suggest that tart cherry and 
exercise may individually enhance bone biomechanical properties, the primary goal of 
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osteoporosis treatment. Additionally, tart cherry exerted improvements in mechanical 
properties independent of mechanical loading while exerting no side effects, thus 
supporting it as a potentially beneficial treatment in osteoporosis prevention. 
 To gain mechanistic insight into the bone microarchitectural changes that 
occurred in response to treatment, systemic and local indicators of osteoblast related bone 
formation and osteoclast related bone resorption were assessed. Serum TRAP, a systemic 
indicator of osteoclastic activity, showed no effects of either treatment. At the tissue 
level, evaluation of regulators of osteoclastogenesis within the femur revealed that the 
key regulator of osteoclastogenesis, Nfatc1, was suppressed by the combination of tart 
cherry and exercise. Only a trend was detected in the down-regulation of c-Fos, and c-
Fms in response to tart cherry and exercise, respectively. Serum OCN, considered a 
systemic indicator of bone turnover and potentially mineralization, was not altered with 
treatment while serum P1NP, a systemic marker of collagen formation, was suppressed 
by tart cherry. The literature suggests that a decrease in serum P1NP concurrent with 
improved bone quality is not uncommon. For example, our lab has reported that dried 
plum supplementation in male mice resulted in a 43% suppression of serum P1NP 
simultaneous with significant increases in BMD, BMC, and trabecular bone volume 
[162]. Investigation of local indicators of osteoblast activity showed that tart cherry 
increased BMP-2 expression by ~80%. BMP-2 is known to stimulate MSC differentiation 
towards an osteoblast lineage via increasing the Runx-2 transcription factor [87]. 
However, Runx2 was not altered after 8 wks of treatment in this study.  Polyphenolic 
compounds from functional foods with similar profiles as tart cherry have been shown to 
upregulate BMP-2 [48] and suppress Nfatc1 in vitro [47]. Thus, it stands to reason that 
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the polyphenolic compounds in tart cherry may be contributing to its effects on bone.  
The incongruence of the local and systemic findings suggests that local responses to tart 
cherry as well as exercise may differ, depending on the site that is being studied. 
Furthermore, the metabolic state of the bone after 8 wks of treatments may not reflect the 
early changes in osteoblast and osteoclast activity that lead to improvements in bone 
structural and biomechanical properties. Serial studies appear to be warranted on order to 
better understand the effects of tart cherry and exercise on bone.   
Functional foods are believed to largely exert their effects via their antioxidant 
and anti-inflammatory properties. Montmorency tart cherries possess a higher total 
phenolic content relative to other cultivars of cherries [143] which is largely composed of 
anthocyanins and hydroxycinnamic acids. The oxygen radical absorption capacity 
(ORAC) for fresh tart cherries was ranked 14th out of 50 foods in terms of antioxidant 
capacity per serving [163]. Ou and colleagues [164] reported that dried tart cherries have 
an ORAC of 6120 per ½ cup (68/gram) serving which was second only to dried plums 
with an ORAC of 6850 per ½ cup serving (81/gram). In terms of indicators of antioxidant 
activity, the relative gene expression of Gpx1 increased by 23% in response to tart cherry. 
However, this response in Gpx1 was blunted when tart cherry was combined with 
exercise. An increase in the relative abundance of Gpx1 may result in an increase in 
glutathione peroxidase which reduces hydrogen peroxide radicals into water thereby 
preventing oxidative stress. Free radicals, which result in oxidative stress, have been 
shown to degenerate bone via a stimulation of IL-1 and subsequent osteoclastic 
resorption [165]. Furthermore, RANKL binding produces free radicals to stimulate 
osteoclastogenesis [166]. Consequently, an increase in glutathione peroxidase may result 
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in enhanced quenching of free radicals and the prevention of RANKL induced 
upregulation of Nfatc1.  
In the current study, FACS analysis of MSC populations showed that it is 
significantly elevated in the exercise groups. These results are in agreement with 
Maredziak and colleagues [34] who reported increased bone marrow MSC populations 
resulting from a chronic exercise regimen. Although not statistically significant, tart 
cherry combined with exercise resulted in a 25% reduction in MSCs compared to 
exercise alone.  Considering this decline in MSCs seen with tart cherry, the tart cherry 
upregulation of BMP-2, and reduction of corticosterone, indicate that tart cherry 
promotes MSCs towards an osteogenic lineage. This notion is supported by Pereira and 
colleagues [167] who reported BMP-2 enhanced MSC osteogenic potential and cortisol 
enhanced MSC adipogenesis. Other sources of polyphenols (e.g., EGCG) have been 
shown to promote osteogenesis of MSCs in vitro, thereby supporting the potential role of 
functional foods to stimulate osteoblast differentiation [135]. Based on the results of the 
current study, we surmise that exercise increased MSC populations in the bone marrow 
while tart cherry promoted their osteogenic lineage allocation via BMP-2 signaling and a 
suppression of corticosterone. This proposed mechanism would need to be confirmed by 
additional analyses but would provide mechanistic insights into the improved bone 
microarchitecture.  
The combination of tart cherry and exercise as a means to prevent osteoporosis is 
an appealing alternative to pharmaceutical options. In this study tart cherry and/or 
exercise enhanced trabecular and cortical bone and biomechanical properties. These 
effects occurred in conjunction with alterations in key regulators of osteogenesis (BMP-
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2) and osteoclastogenesis (Nfatc1), suppression of the stress hormone, corticosterone, and 
the upregulation of Gpx1, a potent antioxidant. Further studies are warranted to clearly 
delineate the role of each of these in the skeletal response to tart cherry and exercise. 
Moreover, clinical trials on the ability of tart cherry and exercise to enhance peak bone 
mass in children are needed. The 10% w/w dosage of tart cherry used in this study is a 
feasible quantity for human consumption (<1/2cup dried tart cherries), supporting 
potential for translation into clinical studies. Overall, tart cherry was at least as effective 
as exercise in its ability to improve bone quality, indicating that it may provide novel 
means of enhancing peak bone mass in the young growing skeleton and ultimately 






SUMMARY, CONCLUSIONS AND RECOMMENDATIONS 
 
Summary 
 This study was designed to determine whether tart cherry affects accrual of bone 
mass in growing animals and whether tart cherry would elicit a synergistic effect with 
exercise. Following a 2-week acclimation period, 4-week-old female C57BL/6 mice were 
assigned to one of four treatment groups (n=12-14mice/group): control (Con), control 
plus exercise (Con/Ex), tart cherry (TC;10% w/w), or TC plus Ex (TC/Ex). Animals were 
subjected to treatment for 8 weeks. At the end of the study the whole body and femur 
bone densitometry, FACS analysis of tibial bone marrow MSC, bone microarchitecture, 
bone biomechanical properties, and systemic and local indicators of osteoblast and 
osteoclast activity and differentiation were assessed. Findings indicate that tart cherry 
primarily affects trabecular bone of long bones and cortical bone of the spine. Systemic 
markers of resorption (i.e. TRAP) and mineralization (i.e. OCN) were not altered by 
treatment, but serum P1NP decreased in response to tart cherry suggesting decreased 
collagen formation. Within the bone tissue, tart cherry upregulated BMP-2, a key 
regulator of osteogenesis and tart cherry combined with exercised downregulated Nfatc1, 
suggesting a local suppression of osteoclastogenesis. MSC populations were increased by 
exercise and tended to be decreased in response to tart cherry. Importantly, tart cherry 
also increased in Gpx1 expression and suppressed serum corticosterone, which may 
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provide additional insight into its effects on the bone microenvironment. These 
observations in conjunction with gene expression data may suggest that exercise 
increases MSC populations and tart cherry promotes their differentiation toward an 




The following is a list of aims and working hypothesis that were proposed for this study: 
Specific Aim 1:  To compare the effects of the tart cherry, exercise, or their combination 
on bone quality (i. e. , BMD, trabecular and cortical microarchitecture, and biomechanical 
properties) in young growing animals.  
Working hypothesis Aim 1: The combination of tart cherry and exercise will yield a 
synergistic effect on bone quality exceeding either variable administered individually. 
 
We reject the hypothesis. Tart cherry and exercise improve bone quality and 
biomechanical properties, but their combination is not synergistic.  Findings showed no 
change in BMD after treatment while BMC was increased (6.31%) by tart cherry. Both 
exercise and tart cherry increased trabecular bone volume in the femur (34%) and spine 
(26.6%), however not synergistically. Similarly, cortical bone in the vertebral body was 
improved (16.1%) by tart cherry and exercise individually. Trabecular biomechanical 
parameters (i.e. stiffness, total force, and Von Mises) in the femur were improved by tart 
cherry while vertebral body parameters were improved by tart cherry and exercise, but 
again not synergistically. Reference point indentation (RPI) of the femoral neck produced 
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synergistic effects on total indentation distance and indentation distance increase, 
however the combination was not significantly improved compared to either variable 
individually. 
 
Specific Aim 2:   To determine the effect of tart cherry, exercise or their combination on 
bone marrow MSC populations and their progression towards an osteoblast lineage.  
Working hypothesis for Aim 2: Tart cherry combined with exercise will result in a 
larger MSC population and a greater potential to form active osteoblasts than either 
variable individually.  
 
We reject the hypothesis. The combination of tart cherry and exercise did not result in a 
greater MSC population than either variable individually. Exercise significantly increased 
the MSC populations (61%) in the bone marrow of the tibia. In contrast, the combination 
of tart cherry and exercise resulted in 25% fewer MSCs than the exercise group. Whether 
the combination promotes a greater potential to form active osteoblasts as a potential 
explanation for the improved bone parameters remains unclear from these findings. 
 
Specific Aim 3:  To assess the alterations in regulators of osteoblast (e.g. Runx2 and 
Osterix) and osteoclast (e.g. RANKL, OPG, and NFatc1) differentiation that occur in 
response to treatments. 
Working hypothesis for Aim 3: The combination of tart cherry and exercise will, to a 
greater magnitude, promote osteoblastogenesis and suppress osteoclastogenesis compared 
to all other treatment groups. 
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We reject the hypothesis. The combination of tart cherry and exercise suppressed Nfatc1 
relative to all other groups. This coincided with trends toward suppression of c-Fos with 
tart cherry and c-Fms with exercise which could lead to the suppression of Nfatc1 and 
osteoclastogenesis, but neither c-Fos nor c-Fms reached the level of statistical 
significance.  Tart cherry alone enhanced BMP2 expression (80%) which could promote 
osteogenesis.  
 
Specific Aim 4:   To evaluate the effects of tart cherry, exercise or their combination on 
osteoblast and osteoclast activity by examining circulating levels of biomarkers of 
resorption (i.e., CTX) and formation (i.e., P1NP) and local indicators of osteoblast 
activity (e.g. ALP, type I collagen), and mineralization (e.g., OCN, Phex, and Ppar-γ), 
and osteoclast activity (e.g. CathK). 
Working hypothesis for Aim 4: Tart cherry and exercise in combination will, to a 
greater magnitude, stimulate osteoblast activity and inhibit osteoclast activity above all 
other treatment groups. 
 
We reject the hypothesis. Serum P1NP was the only activity indicator altered by 
treatment. However, P1NP was suppressed (43%) by tart cherry suggesting reduced 
osteoblast activity. Serum TRAP was unaffected by treatments suggesting no alterations 
in resorption. However, relative abundance of Nfatc1 mRNA was suppressed in the 
femur from the combination treatment suggesting reduced osteoclastogenesis. Lastly, the 
relative abundance of BMP-2 mRNA was decreased in the femur from tart cherry 
suggesting increased osteoblastogenesis. 
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Specific Aim 5: To assess alterations in antioxidant status indicated by gene expression 
of key enzymes involved in scavenging free radicals in bone (e.g. Gpx1 and SOD1) 
resulting from tart cherry, exercise or their combination. 
Working hypothesis for Aim 5: Tart cherry will increase the levels of endogenous 
antioxidant indicators. 
 
We accept the hypothesis. Tart cherry increased the expression of Gpx1 by 23%, 
however the addition of exercise suppressed the tart cherry induced increase in Gpx1. 
 
Recommendations 
 This study suggests some very positive effects of tart cherry supplementation in 
the growing skeleton, however a number of queries remain unanswered. What systemic 
and local alterations are occurring at different time-points throughout the study? What 
local gene effects are occurring at other sites (i.e. vertebral body)? Are transcriptional 
alterations being translated into alterations in protein levels and do tart cherry and 
exercise regulate post-transcriptionally? Do these effects occur in humans? To address 
these questions, future animal studies designed to include a time series study (e.g. 
baseline, 2 wks, 4 wks, and 8 wks) are needed to determine if alterations in systemic and 
local indicators are changing over the progression of treatment. Investigation of local 
indicators of bone formation and resorption in the vertebral body is warranted to provide 
insight relevant to the mechanism by which exercise is exerting a greater effect than in 
the femur. Analysis of protein to determine whether the altered transcription of BMP-2, 
Gpx1, and Nfatc1 is carried out translationally. Furthermore, investigation of protein is 
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needed to assess whether local indicators of osteoblastogenesis (i.e. Runx2), 
osteoclastogenesis (i.e. MCSF), bone formation (i.e. OCN), and bone resorption (i.e. 
CathK) are being translationally regulated as opposed to transcriptionally. This study 
provides evidence that in female growing mice, tart cherry and exercise cause beneficial 
effects on bone quality. However, further studies are needed to delineate the effects of 
tart cherry and exercise on translational regulation, different time points, and different 
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Figure 12. 3D representative images of cortical bone micro-architecture in the (Row I) femoral mid-diaphysis and (Row II) vertebral body.  
















Figure 14. 3D representative images of (A) whole femur rear cut plane and (B) distal femur metaphysis side cut plane. I) femoral neck; II) mid-diaphysis rear view; III) distal 
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